Videos & Podcasts - OncUpdates

Group of four doctors discussing treatment advances in non-squamous NSCLC at OncUpdates.

Aakash Desai, MD, MPH, FASCO

10/02/2026

Aaron Gerds, MD

12/22/2025

Aaron Lisberg, MD

12/31/2025

Multidisciplinary Strategies for Dato-DXd in Pretreated EGFR-Mutated Advanced NSCLC (Full Video)

Aaron Lisberg, MDSarah Sunshine, MDBlanca Ledezma, NPRahul Gosain, MD, MBARohit Gosain, MD

Abhishek Maiti, MD

View All

Abhishek Maiti, MD

01/01/2026

Targeted Combinations Transform AML Care

Abhishek Maiti, MDJorge Cortes, MD

Bispecific antibodies and CAR T-cell therapy for emerging data in TP53-mutated AML and MDS, featuring experts Mycal Casey, DO, and Abishek Maiti, MD, at OncUpdates conference.

Abhishek Maiti, MD

12/24/2025

Reviewing ASH 2025 Data for ALL and TP53-Mutated AML or MDS

Abhishek Maiti, MDMycal Casey, DO

Adam Brufsky, MD, PhD

View All

An informative graphic featuring Dr. Sara Tolaney, Dr. Adam Brufsky, Dr. Rahul Gosain, and Dr. Rohit Gosain discussing the use of CDK4/6 inhibitors in HR+ breast cancer cases.

Adam Brufsky, MD, PhD

11/24/2025

Assessing CDK4/6 Inhibitor Use in HR+ Breast Cancer Cases

Sara Tolaney, MD, MPHAdam Brufsky, MD, PhDRohit Gosain, MDRahul Gosain, MD, MBA

Adriana Penate, MD

View All

Evolving standards in renal cell carcinoma research and treatment, with practical insights for healthcare professionals and oncologists.

Adriana Penate, MD

03/05/2026

Agrima Mian, MD

12/20/2025

Ajai Chari, MD

06/11/2026

CAR T vs BCMA-Directed Bispecific Antibodies: Multiple Myeloma Experts Share Sequencing Insights

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

$Innovative CAR T-cell therapy for relapsed or refractory multiple myeloma, featuring expert insights from Dr. Surbhi Sidana, Dr. Rahul Gosain, Dr. Ajai Chari, and Dr. Binod Dhakal.$

Ajai Chari, MD

06/10/2026

CAR T-Cell Therapy Moves Earlier in Relapsed/Refractory Multiple Myeloma

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Ajinkya Buradkar, MD

View All

Ajinkya Buradkar, MD

01/29/2026

Biomarker Testing and Key Subgroups in Gastric and GEJ Cancer

Ajinkya Buradkar, MDMeghana Singh, MD

Akshee Batra, MD

View All

Lung cancer with tumor showing cancerous growth affecting the bronchi and surrounding lung tissue, emphasizing medical research and oncology treatment.

Akshee Batra, MD

11/14/2025

PALOMA-2: Subcutaneous Amivantamab Plus Lazertinib Delivers MARIPOSA-Level Efficacy with Improved Safety

Akshee Batra, MDChinmay Jani, MD

Alan Bryce, MD

View All

Alan Bryce, MD

03/06/2026

Albert Jang, MD

06/11/2025

Updated CheckMate 214 Results Support Ipi-Nivo for Favorable-Risk Kidney Cancer

Albert Jang, MDMichael Serzan, MD

Alexander Spira, MD, PhD, FACP, FASCO

View All

1. OncUpdates panel featuring leading oncologists discussing advances in EGFR-Mutant NSCLC treatment strategies.

Alexander Spira, MD, PhD, FACP, FASCO

12/30/2025

EP. 5: Closing Perspectives on Advancing Care in EGFR-Positive NSCLC

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

Advances in managing toxicities in Mariposa including IRRs, VTEs, and rash with expert strategies by Dr. Joshua Sabari, Dr. Danny Nguyen, Dr. Alexander Spira, and Dr. Edgardo Santos, featured on OncUpdates.

Alexander Spira, MD, PhD, FACP, FASCO

12/29/2025

Ep. 4: Managing Toxicities in MARIPOSA: Mitigating Treatment-Related Adverse Events

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

OncUpdates panel discussing clinical insights on escalation versus de-escalation in EGFR-positive NSCLC with doctors Joshua Sabari, Danny Nguyen, Alexander Spira, Edgardo Santos, and Eric Singhi.

Alexander Spira, MD, PhD, FACP, FASCO

12/27/2025

Ep. 3: Clinical Insights: Escalation vs De-escalation in EGFR-Positive NSCLC

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

1. Expert panel on CNS activity and resistance discussing Amivantamab and Lazertinib for cancer treatment with Dr. Joshua Sabari, Dr. Edgardo Santos, Dr. Eric Singhi, and Dr. Alexander Spira.

Alexander Spira, MD, PhD, FACP, FASCO

12/21/2025

Ep. 2: CNS Control and Resistance: Panel Examines Amivantamab Plus Lazertinib

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

EGFR-Mutant NSCLC survival updates featuring experts Dr. Danny Nguyen, Dr. Eric Singhi, Dr. Alexander Spira, Dr. Edgardo Santos, and Dr. Joshua Sabari discussing Mariposa & FLAURA2 studies.

Alexander Spira, MD, PhD, FACP, FASCO

12/19/2025

Ep. 1: Overall Survival Updates in EGFR-Positive NSCLC: MARIPOSA and FLAURA2

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

EGFR+ NSCLC metastatic cancer research researchers Dr. Joshua Sabari Dr. Danny Nguyen Dr. Eric Singhi Dr. Alexander Spira Dr. Edgardo Santos oncology clinical insights oncology updates.

Alexander Spira, MD, PhD, FACP, FASCO

12/16/2025

Alexandra Drakaki, MD, PhD

07/23/2026

Experts Review Perioperative Regimens and Potential Future Strategies for Resectable MIBC

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD

Alexis Levee, MD

View All

Alexis Levee, MD

06/12/2026

Breast Oncologists Discuss the Current Paradigm and Future Advancements for ADCs in TNBC

Alexis Levee, MDHope Rugo, MD, FASCO

Medical professionals discussing considerations and clinical trials for early-stage breast cancer treatment.

Alexis Levee, MD

06/10/2026

Oncologists Consider Potential Roles of ADCs in Early-Stage Breast Cancer Treatment

Alexis Levee, MDHope Rugo, MD, FASCO

Alexis Levee, MD

06/09/2026

The Current Paradigm for Selecting and Sequencing ADCs in Metastatic TNBC

Alexis Levee, MDHope Rugo, MD, FASCO

1. Expert doctors Mariam Haji Ahmad and Alexis Levee discuss early use of first-line ADCs in breast cancer treatment and advancements in sequencing technology for improved patient outcomes.

Alexis Levee, MD

01/17/2026

Impact of ADCs in Early TNBC Treatment

Mariam Haji Ahmad, MBBChAlexis Levee, MD

1. Expert discussion on TROP2 ADC options in PD-L1-negative TNBC featuring Alexis LeVee and Paolo Tarantino, MD.

Alexis Levee, MD

01/01/2026

Anti-TROP-2 ADCs in PD-L1-Negative TNBC

Alexis Levee, MDPaolo Tarantino, MD

Ali Al Sbihi, MD

View All

1. Doctor explaining lung cancer scan results to patient with lung model and medical images on computer screen, in a clinical setting.

Ali Al Sbihi, MD

01/25/2026

Top Lung Cancer Advances From 2025

Chinmay Jani, MDAli Al Sbihi, MDGilberto Lopes, MD

Chest X-ray showing lung cancer, medical diagnosis, healthcare, oncology scan, doctor reviewing cancer imaging.

Ali Al Sbihi, MD

11/18/2025

Ivonescimab Plus Chemotherapy in EGFR+ NSCLC After TKI Therapy

Ali Al Sbihi, MDChinmay Jani, MD

Alia Nazarullah, MD

View All

Group of five medical professionals discussing testing and treatment in HR+/HER2- metastatic breast cancer, including Dr. Virginia Kaklamani, Dr. Kevin Kalinsky, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr.

Alia Nazarullah, MD

10/03/2026

Utilizing Inavolisib for Endocrine-Resistant, PIK3CA–mutated, HR+, HER2-, Metastatic Breast Cancer

William Gradishar, MDVirginia Kaklamani, MD, DScKevin Kalinsky, MD, MS, FASCOAlia Nazarullah, MDRahul Gosain, MD, MBARohit Gosain, MD

Alicia Morgans, MD, MPH

View All

Team of medical experts discussing managing toxicities in prostate cancer treatment with androgen receptor pathway inhibitors.

Alicia Morgans, MD, MPH

08/22/2026

A Guide to Managing Toxicities Across Four Androgen Receptor Pathway Inhibitors in Prostate Cancer

Alicia Morgans, MD, MPHChristopher Pieczonka, MDRahul Gosain, MD, MBARohit Gosain, MD

Aman Chauhan, MD

View All

Innovative targeted antibody-drug conjugate for relapsed small cell lung cancer (SCLC) at WCLC 2025. Focus on recent developments in cancer immunotherapy and targeted treatments for lung cancer patients.

Aman Chauhan, MD

11/13/2025

DLL3-Targeted Antibody-Drug Conjugate Reignites Hope for Relapsed SCLC

Asad Rauf, MDChinmay Jani, MDAman Chauhan, MD

Group photo of three doctors, including Dr. Tian Zhang, discussing FDA approval of Cabozantinib for neuroendocrine tumors.

Aman Chauhan, MD

05/16/2025

Amer Zeidan, MBBS, MD

Talha Badar, MBBS, MDAaron Gerds, MDAndrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD

Clinical strategies for diagnosing and treating multiple primary neoplasms (MPNs) in cancer patients, featuring expert insights from Dr. Andrew Kuykendall.

Andrew Kuykendall, MD

08/04/2025

Clinical Strategies for Diagnosing and Treating MPNs

Andrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD

Andrew M. Evens, DO, MBA, MSc

View All

Andrew M. Evens, DO, MBA, MSc

01/15/2026

Angela Alistar, MD

01/21/2026

Perioperative Durvalumab: The New Standard for Gastric or GEJ Cancer

Angela Alistar, MDRahul Gosain, MD, MBARohit Gosain, MDSteven Maron, MD, MScReetu Mukherji, MDRaji Shameem, MD

Angelo Pirozzi, MD

View All

Angelo Pirozzi, MD

01/23/2026

Pancreatic Cancer Highlights From ASCO GI 2026

Fiyinfolu Balogun, MD, PhDAngelo Pirozzi, MD

Antonella Cammarota, PhD

View All

Two medical professionals, a woman and a man, in white coats with a city skyline background, discussing RAS-targeted therapy in pancreatic adenocarcinoma.

Antonella Cammarota, PhD

06/19/2026

Daraxonrasib and the Future of RAS Inhibitors in Pancreatic Cancer

Antonella Cammarota, PhDMichael May, MD

Two medical professionals, a young woman and an older woman, standing in front of a cityscape with a river, discussing evolving hepatocellular carcinoma treatments.

Antonella Cammarota, PhD

06/18/2026

Evolving HCC Treatment: Combining Immunotherapy and TACE

Antonella Cammarota, PhDLorenza Rimassa, MD

Anuja V. Abhyankar, MD

View All

Prognostic criteria and role of Daratumumab in high-risk smoldering myeloma, featuring experts Jing Wang, MD and Anuja Abhyankar, MD, discussing recent advancements in multiple myeloma treatment.

Anuja V. Abhyankar, MD

01/08/2026

Early Intervention Strategies in High-Risk Smoldering Multiple Myeloma

Anuja V. Abhyankar, MDJing Wang, MD

$1. Researchers and clinicians discuss strategies for managing lenalidomide, CD38, and multi-refractory disease in relapsed multiple myeloma treatment at OncUpdates conference.$

Anuja V. Abhyankar, MD

01/04/2026

How to Select Treatment in Relapsed Multiple Myeloma

Anuja V. Abhyankar, MDS. Vincent Rajkumar, MD

Uncancerous blood cells and white blood cells circulating in a blood vessel for medical research and oncology updates.

Anuja V. Abhyankar, MD

08/15/2025

The Impact of Novel Agents in Non-Hodgkin Lymphoma Treatment

Anuja V. Abhyankar, MD

Anupriya Singhal, MD, PhD

View All

Advances in pancreatic and biliary tract cancers at ASCO GI 2026, expert insights, oncology research, cancer treatment innovations, medical conference, OncUpdates.

Anupriya Singhal, MD, PhD

02/08/2026

Advances in Pancreatic and Biliary Tract Cancers at ASCO GI 2026: Expert Insights

Anupriya Singhal, MD, PhD

Anwaar Saeed, MD

View All

CBADet, MSS Colorectal Cancer, and Emerging Practice-Changing Data in Oncology research and updates.

Anwaar Saeed, MD

01/21/2026

CABINET and STELLAR-303 Trials Inform Treatment in NETs and mCRC

Nicholas Hornstein, MD, PhDAnwaar Saeed, MD

Arthi Sridhar, MD

View All

Two medical professionals, a woman and a man, stand in front of a city skyline with a banner reading 'Expanding Precision Therapy in Lung Cancer' for OncUpdates.

Arthi Sridhar, MD

06/26/2026

The Growing Role of Precision Medicine Across Lung Cancers

Stephen Liu, MDArthi Sridhar, MD

Two female doctors, Arth Sridhar and Narjust Florez, smiling in front of a city skyline, discussing NSCLC trial updates for HARMONi-6 and LIBRETTO-432.

Arthi Sridhar, MD

06/22/2026

Articles

06/24/2026

EHA 2026: Ziftomenib Plus Intensive Induction Shows Deep Durable Responses in Newly Diagnosed NPM1-Mutant or KMT2A-Rearranged AML

Sawyer Bawek, DO

$Teclistamab monotherapy shown as a promising treatment for multiple myeloma, highlighting survival benefits in early relapsed or refractory cases.$

Sawyer Bawek, DO

Immune cells attacking cancer cells in the bloodstream, illustrating cancer immunotherapy and blood cancer treatment strategies.

Articles

10/09/2025

Real-World Evidence Supports Outpatient Axicabtagene Ciloleucel (Yescarta) Administration for Relapsed/Refractory LBCL

Sawyer Bawek, DO

Articles

08/15/2025

The Impact of Novel Agents in Non-Hodgkin Lymphoma Treatment

Anuja V. Abhyankar, MD

Malignant cell division illustration showing cancer cells attacking the human immune system and bloodstream, emphasizing oncology research and targeted cancer therapies.

Articles

07/28/2025

Management of Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory Disease

Vaishali Deenadayalan, MD

Detailed 3D rendering of human lungs showing the bronchial tubes, arteries, and veins for educational medical or respiratory health content.

Articles

05/28/2025

IMforte Trial: A Potential First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Sawyer Bawek, DO

Lung cancer illustration showing tumor growth inside the lung with detailed respiratory system anatomy.

Articles

05/26/2025

Arya Mariam Roy, MD

06/10/2025

Integrating Metastatic Triple-Negative Breast Cancer NCCN Guidelines Into Clinical Practice

Arya Mariam Roy, MDHope Rugo, MD, FASCO

Arya Mariam Roy, MD

06/10/2025

ASCENT-04 Trial: First-Line Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1+ TNBC

Arya Mariam Roy, MDHope Rugo, MD, FASCO

Asad Rauf, MD

View All

Asad Rauf, MD

11/13/2025

DLL3-Targeted Antibody-Drug Conjugate Reignites Hope for Relapsed SCLC

Asad Rauf, MDChinmay Jani, MDAman Chauhan, MD

Ashish M. Kamat, MD, MBBS, FACS

View All

Ashish M. Kamat, MD, MBBS, FACS

07/31/2026

Ep. 4: Personalizing Perioperative Treatment for Muscle-Invasive Bladder Cancer With NIAGARA and EV-Based Regimens

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD

Ashish M. Kamat, MD, MBBS, FACS

07/30/2026

Ep. 3: Selecting Perioperative Therapy for Muscle-Invasive Bladder Cancer Based on Patient and Tumor Characteristics

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD

Ashish M. Kamat, MD, MBBS, FACS

07/26/2026

Ep. 2: Perioperative Muscle-Invasive Bladder Cancer: Interpreting pCR, Survival, and Treatment Selection

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD

Ashish M. Kamat, MD, MBBS, FACS

07/24/2026

Ep. 1: NIAGARA and EV-Based Perioperative Therapy Reshape Treatment for Muscle-Invasive Bladder Cancer

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD

Ashish M. Kamat, MD, MBBS, FACS

07/23/2026

Experts Review Perioperative Regimens and Potential Future Strategies for Resectable MIBC

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD

Enhanced immunotherapy plus BCG treatment for high-risk non-muscle invasive bladder cancer; two doctors in formal attire with cityscape background.

Ashish M. Kamat, MD, MBBS, FACS

03/08/2026

Immunotherapy Plus BCG Shows Promise in NMIBC: Insights From POTOMAC and CREST

Ashish M. Kamat, MD, MBBS, FACSVishesh Khanna, MD

Aslihan Yerlikaya, MD

View All

Aerial view of a city skyline with a waterfront, highlighting the latest insights from ASCO 2026 on evolving treatment strategies for gastrointestinal cancers.

Aslihan Yerlikaya, MD

06/07/2026

Insights From ASCO 2026: Evolving Treatment Strategies in Gastrointestinal Malignancies

Aslihan Yerlikaya, MD

Balazs Halmos, MD

View All

WCLC 2025 oncology conference highlights featuring key researchers discussing FLURA2, HARMONI, and ALCHEMIST targeted therapies for lung cancer treatment.

Balazs Halmos, MD

10/08/2025

Key NSCLC Trials From WCLC 2025

Balazs Halmos, MDRahul Gosain, MD, MBARohit Gosain, MD

Ben Derman, MD

View All

A groundbreaking presentation on AQUILA, COBRA, TecLLE, and MajesTEC-3 trials highlighting innovative signal shifts in myeloma management by leading oncology experts.

Ben Derman, MD

02/24/2026

Benjamin Leon Musher, MD

05/31/2026

Benjamin Levy, MD

06/18/2026

Beth Faiman, CNP, PhD

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

$Innovative CAR T-cell therapy for relapsed or refractory multiple myeloma, featuring expert insights from Dr. Surbhi Sidana, Dr. Rahul Gosain, Dr. Ajai Chari, and Dr. Binod Dhakal.$

Binod Dhakal, MD

06/10/2026

CAR T-Cell Therapy Moves Earlier in Relapsed/Refractory Multiple Myeloma

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Close-up of Verenzo (bevemacil) 50 mg tablets in packaging, used for erectile dysfunction treatment, displayed on a white background.

Binod Dhakal, MD

06/05/2026

CAR T in Myeloma: Earlier Use and Sequencing Insights from ASCO 2026

Binod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Bita Fakhri, MD, MPH

View All

1. Expert insights on frontline BTK inhibitors and triplet therapy for CLL at ASH 2025, featuring Mahesh Swaminathan and Bita Fakhri.

Bita Fakhri, MD, MPH

Aaron Lisberg, MDSarah Sunshine, MDBlanca Ledezma, NPRahul Gosain, MD, MBARohit Gosain, MD

Blanca Ledezma, NP

12/31/2025

Bradley McGregor, MD

12/06/2025

Treating Advanced RCC After First-Line Therapy (Full Video)

David Braun, MD, PhDBradley McGregor, MDUlka Vaishampayan, MBBSRahul Gosain, MD, MBARohit Gosain, MD

Brandi Reeves, MD

View All

Panel discussion on management of treatment-related toxicities in polycythemia vera featuring Dr. Brandi Reeves, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Naveen Pemmaraju.

Brandi Reeves, MD

09/14/2026

The Management of Treatment-Related Toxicities in Polycythemia Vera

Naveen Pemmaraju, MDBrandi Reeves, MDRahul Gosain, MD, MBARohit Gosain, MD

Brendan Guercio, MD

View All

Dr. Brendan Guercio and Dr. Tian Zhang discuss perioperative strategies for high-risk localized prostate cancer at ASCO 2026.

Brendan Guercio, MD

06/25/2026

Practice-Changing Updates for Prostate Cancer From ASCO 2026

Brendan Guercio, MDTian Zhang, MD, MHS

Brendan Guercio, MD

05/13/2026

TKIs After Upfront Immunotherapy in Metastatic RCC: A Practical Review

Brendan Guercio, MD

HER2-Directed Strategies in Urothelial Cancer, featuring Dr. Miles Hsu and Dr. Brendan Guercio discussing innovative treatments for bladder cancer, with a cityscape background.

Brendan Guercio, MD

03/15/2026

Novel HER2–Targeting Therapies in Urothelial Cancer

Brooke Kania, DO

06/06/2026

TALAPRO-3: A Major rPFS Win in HRR-Mutated mCSPC, But Which Patients Benefit Most?

Brooke Kania, DO

Advanced molecular testing and targeted therapies for prostate cancer research and treatment.

Brooke Kania, DO

03/16/2026

ASCO GU 2026: Experts Highlight Key Updates in Prostate Cancer

Brooke Kania, DOSindhuja Kadambi, MD, MS

Caitlin Costello, MD

View All

Group photo of three doctors discussing CAR T-Cell Therapy in Multiple Myeloma, highlighting collaboration and adverse effects management.

Caitlin Costello, MD

08/04/2026

CAR T-Cell Therapy in Multiple Myeloma: Managing Adverse Effects Through Collaboration

Caitlin Costello, MDJoshua Richter, MDRahul Gosain, MD, MBARohit Gosain, MD

Carla Casulo, MD

View All

Group photo of three medical professionals discussing lymphoma presentations at EHA 2026.

Carla Casulo, MD

07/31/2026

4 Key Lymphoma Presentations From EHA 2026

Carla Casulo, MDRahul Gosain, MD, MBARohit Gosain, MD

$Bioscientists discussing targeted bispecific antibody therapies in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) at OncUpdates conference.$

Carla Casulo, MD

07/22/2025

Selecting Bispecific Antibody Therapies in RR DLBCL

Carla Casulo, MDTara Graff, DO, MS

Catherine Coombs, MD

View All

1. Two healthcare professionals, a male and female doctor, smiling against a city skyline at dusk, promoting oncology research updates on BTK inhibitors and therapy in CLL.

Catherine Coombs, MD

12/17/2025

SEQUOIA Trial Long-Term Data Support Second-Generation BTK Inhibitors in CLL

Catherine Coombs, MDDaniel Ermann, MD

Cathy Eng, MD, FACP, FASCO

View All

Cathy Eng, MD, FACP, FASCO

06/25/2026

EPISODE-III and RASolute 302 Data From ASCO 2026

Carolina Bernabe Ramirez, MDCathy Eng, MD, FACP, FASCO

Five major colorectal and gastrointestinal cancer abstracts from 2025 ASCO conference, analyzed by oncologists with insights on latest research and breakthroughs in cancer treatment.

Cathy Eng, MD, FACP, FASCO

06/27/2025

Chad Reichard, MD

03/09/2026

Clinical Insights: Evolving Landscapes in MIBC and NMIBC

Rahul Gosain, MD, MBARohit Gosain, MDShilpa Gupta, MDChad Reichard, MDSia Daneshmand, MDMatt Galsky, MD

Charbel Matar, MD

View All

View All

Chinmay Jani, MD

09/25/2026

CROWN at 7 Years: A New Benchmark for Durable Disease Control in ALK-Positive NSCLC

Diya JayramChinmay Jani, MDGilberto Lopes, MD

Chinmay Jani, MD

06/09/2026

Key ASCO 2026 Updates in NSCLC and SCLC

Chinmay Jani, MDTessa Lavorgna, MD

Overview of thoracic oncology highlights at ASCO 2026, focusing on lung cancer research and treatment updates for oncologists and medical professionals.

Chinmay Jani, MD

05/28/2026

What to Watch at ASCO 2026: A Thoracic Oncologist’s Guide to the Lung Cancer Program

Dan Morgenstern, MDChinmay Jani, MDGilberto Lopes, MD

Chinmay Jani, MD

05/18/2026

Beyond Osimertinib Monotherapy: Frontline Intensification in EGFR-Mutant NSCLC After FLAURA2 and MARIPOSA

Chinmay Jani, MDRuchi JaniGilberto Lopes, MD

Chinmay Jani, MD

03/15/2026

Ep. 3: Intensification Strategies and CNS Management in EGFR-Mutant NSCLC

Chinmay Jani, MDLuis Raez, MD, FACP, FCCP, FASCO

Chinmay Jani, MD

03/13/2026

Ep. 2: Subcutaneous Amivantamab Reshapes Frontline EGFR-Mutant NSCLC Care

Chinmay Jani, MDLuis Raez, MD, FACP, FCCP, FASCO

Chinmay Jani, MD

03/11/2026

Ep. 1: Overcoming Infusion Barriers in EGFR-Mutant Non–Small Cell Lung Cancer

Chinmay Jani, MDLuis Raez, MD, FACP, FCCP, FASCO

Chinmay Jani, MD

01/25/2026

Top Lung Cancer Advances From 2025

Chinmay Jani, MDAli Al Sbihi, MDGilberto Lopes, MD

Chinmay Jani, MD

11/18/2025

Ivonescimab Plus Chemotherapy in EGFR+ NSCLC After TKI Therapy

Ali Al Sbihi, MDChinmay Jani, MD

Malignant tumor in the lung with cancerous growth and tumor cells, medical illustration of lung cancer pathology for oncology and cancer research.

Chinmay Jani, MD

11/17/2025

Dual Targeting: Iza-bren Shows Promising Early Results Across Solid Tumors

Samantha El Warrak, MBBSChinmay Jani, MD

Chinmay Jani, MD

11/14/2025

PALOMA-2: Subcutaneous Amivantamab Plus Lazertinib Delivers MARIPOSA-Level Efficacy with Improved Safety

Akshee Batra, MDChinmay Jani, MD

Chinmay Jani, MD

11/13/2025

DLL3-Targeted Antibody-Drug Conjugate Reignites Hope for Relapsed SCLC

Asad Rauf, MDChinmay Jani, MDAman Chauhan, MD

CT scan of a chest showing lung health, used in cancer diagnosis and treatment monitoring.

Chinmay Jani, MD

11/12/2025

Chemotherapy Plus Osimertinib Offers Overall Survival Benefit in EGFR-mutated NSCLC

Daniel Tuerff, MDChinmay Jani, MDEstelamari Rodriguez, MD, MPH

Oncoupdates, oncology conference, medical professionals, cancer research, healthcare presentation, cancer awareness, medical event, oncology advancements, professional networking, cancer treatment innovation.

Chinmay Jani, MD

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Christopher Pieczonka, MD

View All

Christopher Pieczonka, MD

08/22/2026

A Guide to Managing Toxicities Across Four Androgen Receptor Pathway Inhibitors in Prostate Cancer

Alicia Morgans, MD, MPHChristopher Pieczonka, MDRahul Gosain, MD, MBARohit Gosain, MD

Claudia Villa Celi, MD

View All

Claudia Villa Celi, MD

Matthew Kurian, MDWassim McHayleh, MDEleonora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD

Group of five medical researchers discussing translating SENTRY data into clinical practice.

Charu Aggarwal, MD, MPHSamuel Caughron, MDPaolo Tarantino, MDRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

07/28/2026

The Role of Imetelstat in Lower-Risk Myelodysplastic Syndromes

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

OncUpdates episode 4 features experts discussing FLT3-Positive AML targeted therapy from diagnosis through long-term management.

Clinical Insights

07/28/2026

Ep. 4: FLT3-Mutated AML: Targeted Therapy From Diagnosis Through Long-Term Management

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

OncUpdates episode 3 featuring experts discussing FLT3-mutated AML, maintenance therapy, triplet regimens, and relapse management.

Clinical Insights

07/27/2026

Ep. 3: FLT3-Mutated AML: Maintenance Therapy, Triplet Regimens, and Relapse Management

Benjamin Levy, MDJarushka Naidoo, MB, BCh, MHSBo Wang, MD

Clinical Insights

06/18/2026

Clinical Insights: The HARMONi-6 Trial and Dual PD-1/VEGF Blockade in Squamous Lung Cancer

Benjamin Levy, MDJarushka Naidoo, MB, BCh, MHSBo Wang, MD

Panel discussion on managing toxicity and expanding RAS therapy in pancreatic cancer featuring Dr. Andrew H. Ko, Dr. Eileen O'Reilly, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Rachna Shroff, and Dr. Shu.

Clinical Insights

06/16/2026

Managing Toxicity and Expanding RAS Therapy in Pancreatic Cancer

Andrew H. Ko, MDEileen O'Reilly, MDShubham Pant, MD, MBBSRachna Shroff, MD, MS, FASCORahul Gosain, MD, MBARohit Gosain, MD

Panel of oncology experts discussing the clinical impact of RASolution 302 in doubling patient survival.

Clinical Insights

06/15/2026

Doubling Survival: The Clinical Impact of RASolute 302

Andrew H. Ko, MDEileen O'Reilly, MDShubham Pant, MD, MBBSRachna Shroff, MD, MS, FASCORahul Gosain, MD, MBARohit Gosain, MD

Panel discussion on drug development and clinical success in RAS-driven cancer, featuring experts Dr. Andrew H. Ko, Dr. Eileen O'Reilly, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Rachna Shroff, and Dr.

Clinical Insights

06/14/2026

From Drug Design to Phase 3 Success in RAS-Driven Disease

Andrew H. Ko, MDEileen O'Reilly, MDShubham Pant, MD, MBBSRachna Shroff, MD, MS, FASCORahul Gosain, MD, MBA

Clinical Insights

06/13/2026

The Emerging Role of RAS Inhibitors in Pancreatic Cancer

Midhun Malla, MDMichael A. Morse, MD, FACP, MHSBenjamin Leon Musher, MDRahul Gosain, MD, MBARohit Gosain, MD

Dr. Andrew H. Ko, Dr. Eileen O'Reilly, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Rachna Shroff, Dr. Shubham Panti discuss Daraxonrasib's impact on pancreatic cancer survival.

Clinical Insights

06/13/2026

Daraxonrasib Delivers Breakthrough Survival Gains in Pancreatic Cancer

Andrew H. Ko, MDEileen O'Reilly, MDShubham Pant, MD, MBBSRachna Shroff, MD, MS, FASCORahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

06/12/2026

Dose Optimization and Pharmacogenomic Testing in Pancreatic Cancer Treatment

Midhun Malla, MDMichael A. Morse, MD, FACP, MHSBenjamin Leon Musher, MDRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

06/12/2026

The Treatment Paradigm for Low-Risk MDS and the Impact of Luspatercept

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Clinical Insights

06/12/2026

Multiple Myeloma Experts Highlight Real-World Safety and Care Coordination Following CAR T-Cell Therapy

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of medical experts discussing immunotherapy, bladder cancer, and multidisciplinary care for non-muscle invasive bladder cancer (NMIBC).

Clinical Insights

06/11/2026

Real-World Integration, Immune Toxicity, and the Future of Multidisciplinary NMIBC Care

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

06/11/2026

Treatment Selection and Future Directions in Polycythemia Vera

Aaron Gerds, MDAnthony M. Hunter, MDAnand Patel, MDRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

06/11/2026

CAR T vs BCMA-Directed Bispecific Antibodies: Multiple Myeloma Experts Share Sequencing Insights

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

06/10/2026

Molecular Responses and Long-Term Disease Control in Polycythemia Vera

Aaron Gerds, MDAnthony M. Hunter, MDAnand Patel, MDRahul Gosain, MD, MBARohit Gosain, MD

$Innovative CAR T-cell therapy for relapsed or refractory multiple myeloma, featuring expert insights from Dr. Surbhi Sidana, Dr. Rahul Gosain, Dr. Ajai Chari, and Dr. Binod Dhakal.$

Clinical Insights

06/10/2026

CAR T-Cell Therapy Moves Earlier in Relapsed/Refractory Multiple Myeloma

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

06/09/2026

Optimizing Ropeginterferon Use in Polycythemia Vera

Aaron Gerds, MDAnthony M. Hunter, MDAnand Patel, MDRahul Gosain, MD, MBARohit Gosain, MD

Medical panel discussing Potomac trial results on Durvalumab and BCG therapy improving recurrence-free survival in cancer patients.

Clinical Insights

06/09/2026

POTOMAC Trial Breakthrough: Durvalumab Plus BCG Shows Improved Recurrence-Free Survival

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Key oncology trial highlights Durvalumab and BCG combination improving disease-free survival, featuring experts Dr. Shilpa Gupta, Dr. Neal Shore, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Amit Patel.

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Expert discussion on the role of Amivantamab in treating head and neck cancer, featuring leading oncologists Dr. Barbara Burtness, Dr. Paul Swiecicki, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Ari Rosen.

Clinical Insights

06/02/2026

Clinical Insights: Role of Amivantamab in Head and Neck Cancer

Barbara Burtness, MDAri Rosenberg, MDJessica Geiger, MDPaul Swiecicki, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of medical experts discussing the impact of RASolute 302 on clinical practice for metastatic pancreatic ductal adenocarcinoma (PDAC).

Clinical Insights

06/02/2026

Clinical Insights: Impact of RASolute 302 on Clinical Practice in Previously Treated Metastatic PDAC

Andrew H. Ko, MDShubham Pant, MD, MBBSEileen O'Reilly, MDRachna Shroff, MD, MS, FASCORahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

05/31/2026

Clinical Insights: Evolving Paradigms in Metastatic Pancreatic Cancer

Midhun Malla, MDMichael A. Morse, MD, FACP, MHSBenjamin Leon Musher, MDRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

05/31/2026

Clinical Insights: Role of Ropeginterferon Alfa-2b-njft in Polycythemia Vera

Aaron Gerds, MDAnthony M. Hunter, MDAnand Patel, MDRahul Gosain, MD, MBARohit Gosain, MD

Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC - OncUpdates featuring Dr. Julia Rotow, Dr. Fawzi Abu Rous, Dr. Sarah Goldberg, and Dr. Susan Scott discussing recent advances in.

Clinical Insights

03/19/2026

Ep. 3: Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC

Eric Singhi, MDSarah Goldberg, MD, MPHFawzi Abu Rous, MDJulia Rotow, MDSusan Scott, MD

Proactive toxicity management and CNS control in EGFR-mutant NSCLC discussed by leading oncologists at OncUpdates conference. Expert insights on personalized treatment strategies.

Clinical Insights

03/17/2026

Ep. 2: Clinical Insights: Proactive Toxicity Management and CNS Control in EGFR-Mutant NSCLC

Eric Singhi, MDSarah Goldberg, MD, MPHSusan Scott, MDFawzi Abu Rous, MDJulia Rotow, MD

Clinical Insights

03/15/2026

Ep. 3: Intensification Strategies and CNS Management in EGFR-Mutant NSCLC

Chinmay Jani, MDLuis Raez, MD, FACP, FCCP, FASCO

Clinical Insights

03/15/2026

Ep. 4: Multidisciplinary Approaches to Emerging Bladder Cancer Treatments

Rahul Gosain, MD, MBARohit Gosain, MDMatt Galsky, MDSia Daneshmand, MDChad Reichard, MDShilpa Gupta, MD

OS Benefit and Patient-Centered Delivery Advances in EGFR-Positive NSCLC, featuring Dr. Eric Singhi, Dr. Julia Rotow, Dr. Susan Scott, Dr. Sarah Goldberg, and Dr. Fawzi Abu Rous discussing recent onco.

Aaron Lisberg, MDSarah Sunshine, MDBlanca Ledezma, NPRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

01/12/2026

EP. 3: Monitoring, Dosing, and Rechallenge Strategies With Datopotamab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Aaron Lisberg, MDSarah Sunshine, MDBlanca Ledezma, NPRahul Gosain, MD, MBARohit Gosain, MD

OncUpdates panel discussing Abemaciclib vs Ribociclib for clinical decision-making and improving quality of life in cancer patients, featuring expert oncologists Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Laura Huppert, Dr. Komal Jhaveri, Dr. Hope Rugo, and Dr. Heather McArthur.

Clinical Insights

01/12/2026

Ep. 3: Abemaciclib vs Ribociclib: Clinical Decision-Making for Quality of Life

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

01/11/2026

Ep. 2: Managing Ocular Toxicity, Mucositis, and ILD With Datopotamab Deruxtecan in EGFR-Mutated NSCLC

Aaron Lisberg, MDSarah Sunshine, MDBlanca Ledezma, NPRahul Gosain, MD, MBARohit Gosain, MD

1. OncUpdates panel discussing metastatic HR+ breast cancer and CDK4/6 inhibitor treatment options with leading oncology experts.

Clinical Insights

01/10/2026

Ep. 2: Metastatic HR-Positive Breast Cancer: Choosing the Right CDK4/6 Inhibitor

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

01/10/2026

Ep. 4: Managing Fatigue and Phlebotomy Burden in PV With Rusfertide

Talha Badar, MBBS, MDAaron Gerds, MDAndrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

01/09/2026

Ep. 1: Efficacy, Safety, and Management of Dato-DXd in EGFR-Mutated Lung Cancer

Aaron Lisberg, MDSarah Sunshine, MDBlanca Ledezma, NPRahul Gosain, MD, MBARohit Gosain, MD

Early-Stage HR+ Breast Cancer treatment update on managing CDK4/6 inhibitor sequencing with expert physicians at OncUpdates.

Clinical Insights

01/09/2026

Ep. 4: Early-Stage HR-Positive Breast Cancer: Managing CDK4/6 Inhibitor Sequencing

Sara Hurvitz, MD, FACPSherry Shen, MDEleonora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

01/08/2026

Ep. 3: Managing Hematocrit and Symptoms in PV: Dose-Titration Strategies for Rusfertide

Talha Badar, MBBS, MDAaron Gerds, MDAndrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD

Liver toxicity research with expert doctors discussing risk stratification and personalized adjuvant therapy in early-stage HR+ breast cancer treatment.

Clinical Insights

01/07/2026

Ep. 3: Liver Toxicity, Risk Stratification, and Personalized Adjuvant Therapy in Early-Stage HR-Positive Disease

Sara Hurvitz, MD, FACPSherry Shen, MDEleonora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

01/06/2026

Ep. 1: Clinical Insights: Optimizing Ribociclib, Abemaciclib, and Palbociclib Use in Metastatic HR-Positive Breast Cancer

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

01/06/2026

Ep. 2: Integrating Rusfertide Into the Polycythemia Vera Treatment Algorithm

Talha Badar, MBBS, MDAaron Gerds, MDAndrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD

1. Expert panel on practical guidance for Ribociclib and Abemaciclib in adjuvant cancer therapy, featuring leading oncologists discussing advanced treatment strategies.

Clinical Insights

01/05/2026

Ep. 2: Practical Guidance for Ribociclib and Abemaciclib in the Adjuvant Setting

Sara Hurvitz, MD, FACPSherry Shen, MDEleonora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

01/03/2026

Ep. 1: Adjuvant Ribociclib in Early-Stage HR-Positive Breast Cancer: Clinical Insights

Sara Hurvitz, MD, FACPSherry Shen, MDEleonora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

01/02/2026

Ep. 1: Clinical Insights: New Approaches to Hematocrit Control in Polycythemia Vera

Talha Badar, MBBS, MDAaron Gerds, MDAndrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

12/31/2025

Multidisciplinary Strategies for Dato-DXd in Pretreated EGFR-Mutated Advanced NSCLC (Full Video)

Aaron Lisberg, MDSarah Sunshine, MDBlanca Ledezma, NPRahul Gosain, MD, MBARohit Gosain, MD

1. Expert panel discusses CDK4/6 inhibitors in metastatic breast cancer at OncUpdates, featuring leading oncologists and researchers.

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

Adjuvant CDK4/6 therapy in early HR+ breast cancer, featuring Dr. Eleonora Teplinsky, Dr. Sherry Shen, Dr. Rahul Gosain, Dr. Sara Hurwitz, and Dr. Rohit Gosain, with clinical insights and expertise.

David Braun, MD, PhDUlka Vaishampayan, MBBSBradley McGregor, MDRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

12/08/2025

Ep. 2: VEGF TKIs in RCC: Toxicity and Tolerability

David Braun, MD, PhDBradley McGregor, MDRahul Gosain, MD, MBARohit Gosain, MD

Clinical Insights

12/07/2025

Ep. 1: Positioning Tivozanib in Today’s RCC Treatment Landscape

Clinical Insights

06/15/2025

MARIPOSA: Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC

Estelamari Rodriguez, MD, MPHHelena Yu, MDJoshua Sabari, MDSusan Scott, MDRahul Gosain, MD, MBARohit Gosain, MD

1. Expert oncologists presenting research on NIAGARA trial and perioperative durvalumab treatment for MIBC.

Clinical Insights

06/14/2025

Conferences

08/03/2026

Key Leukemia and Myelofibrosis Presentations at EHA 2026

Eunice Wang, MDRahul Gosain, MD, MBARohit Gosain, MD

Conferences

07/31/2026

4 Key Lymphoma Presentations From EHA 2026

Carla Casulo, MDRahul Gosain, MD, MBARohit Gosain, MD

Two doctors, Dr. Rahul Banerjee and Dr. Rohit Gosain, featured in a digital graphic about emerging data for CELMoDs in multiple myeloma.

Conferences

07/22/2026

The Emerging Data for CELMoDs in Multiple Myeloma

Conferences

06/29/2026

SARC041: Establishing CDK4/6 Inhibition as a New Treatment Option in Dedifferentiated Liposarcoma

Samantha Armstrong, MD

Conferences

06/26/2026

ASCO 2026: Key Lymphoma Data From the frontMIND and SUNMO Trials

Sawyer Bawek, DOAgrima Mian, MD

Conferences

06/26/2026

The Growing Role of Precision Medicine Across Lung Cancers

Conferences

06/20/2026

Talquetamab Side Effects: Management and Counseling Strategies

Sawyer Bawek, DOHamza Hashmi, MD

City street scene with theater marquee and skyscrapers, highlighting recent advances in GU cancers from ASCO 2026.

Conferences

06/19/2026

Practice-Changing Shifts in GU Cancers From ASCO 2026

Manas Pustake, MD

Conferences

06/18/2026

Phase 3 RASolute 302 Trial: Groundbreaking Data for Daraxonrasib in mPDAC

Brian Wolpin MD MPHRahul Gosain, MD, MBARohit Gosain, MD

Conferences

06/18/2026

Evolving HCC Treatment: Combining Immunotherapy and TACE

Antonella Cammarota, PhDLorenza Rimassa, MD

Cityscape with river and skyscrapers, highlighting new cancer treatment developments in head and neck cancer research.

Conferences

06/17/2026

From Resistance to Response: Amivantamab Opens a New Chapter in Head and Neck Cancer

Coral Olazagasti, MD

Two medical professionals, Sawyer Bawek and Hamza Hashmi, discuss Teclistamab in earlier treatment lines for multiple myeloma with a city skyline background.

Conferences

06/17/2026

MajesTEC-9 Data and Teclistamab in Earlier Treatment Lines for Multiple Myeloma

Sawyer Bawek, DOHamza Hashmi, MD

Conferences

06/17/2026

GU Experts Weigh In on Trials That Could Redefine Bladder, Kidney, and Prostate Cancer Care

Andre Kydd, MD, PhD

Two medical professionals, Sawyer Bawek DO and Hamza Hashmi MD, discuss the evolution of CAR T-cell therapy against a cityscape background.

Conferences

06/16/2026

The Growing Role of CAR T-Cell Therapies in Multiple Myeloma

Sawyer Bawek, DOHamza Hashmi, MD

Image showing the ASCO 2026 conference banner with the study title on a city skyline background, highlighting advancements in multiple myeloma treatment.

Conferences

06/16/2026

ASCO 2026: Mezigdomide Plus Kd Doubles PFS in Heavily Pretreated Multiple Myeloma in SUCCESSOR-2

Sawyer Bawek, DO

Aerial view of New York City skyline with river and park, highlighting advancements in pancreatic cancer treatment.

Conferences

06/15/2026

Daraxonrasib Delivers Game-Changing Survival Benefit in Previously Treated PDAC

Sunnie Kim, MD

Conferences

06/15/2026

RASolute 302: Evaluating the Side Effect Profile of Daraxonrasib

Shiraj Sen, MD, PhDRaji Shameem, MD

Visual representation of integrating circulating tumor DNA (ctDNA) into muscle-invasive bladder cancer treatment strategies, with a city skyline background.

Conferences

06/14/2026

Integrating ctDNA Into Muscle-Invasive Bladder Cancer Treatment

Miles Hsu, MD

Insights from ASCO 2026 on antibody-drug conjugates reshaping metastatic triple-negative breast cancer treatment.

Conferences

06/14/2026

Insights from ASCO 2026: Antibody–Drug Conjugates Continue to Reshape Metastatic Triple-Negative Breast Cancer

Stephanie Haddad, DO

HPV-negative head and neck squamous cell carcinoma research, treatment strategies, and clinical insights by Nicole Dalal, MD, and Fangdi Sun, MD.

Conferences

06/13/2026

Emerging Data on Amivantamab and Other Anti-EGFR Bispecifics in Head and Neck Cancer

Nicole Dalal, MDFangdi Sun, MD

Conferences

06/12/2026

Breast Oncologists Discuss the Current Paradigm and Future Advancements for ADCs in TNBC

Alexis Levee, MDHope Rugo, MD, FASCO

Molecular profiling and treatment sequencing in HR-positive breast cancer with Dr. Ya Haddy Sallah and Dr. Jimmitti Teysir.

Conferences

06/12/2026

How Molecular Profiling Guides Targeted Therapy Options in HR–Positive Breast Cancer

Jimmitti Teysir, MDYa Haddy Sallah, MD, MPH

Overview of GLP-1 receptor agonists and their role in breast cancer treatment, featuring insights from Cleveland Clinic expert Jasmin Hundal, MD, MS, MPH.

Conferences

06/11/2026

GLP-1 Receptor Agonists in Breast Cancer: Moving Beyond Weight Loss Toward Cancer Prevention and Survivorship

Jasmin Hundal, MD

Experts discuss innovative treatment strategies for metastatic ER-positive breast cancer against a city skyline at sunset. Focus on oncology, breast cancer, and advanced therapies.

Conferences

06/11/2026

How To Approach Endocrine Therapies for Metastatic Breast Cancer in the Adjuvant CDK4/6 Inhibitor Era

Jasmin Hundal, MDDionisia Quiroga, DO, PhD

Conferences

06/10/2026

Oncologists Consider Potential Roles of ADCs in Early-Stage Breast Cancer Treatment

Alexis Levee, MDHope Rugo, MD, FASCO

ASCO 2026 presentation on Giredestrant for ER+/HER2- metastatic breast cancer at Roswell Park Cancer Center.

Conferences

06/10/2026

ASCO 2026: Evaluating Giredestrant in First-Line ER+/HER2- Metastatic Breast Cancer

Vaishali Deenadayalan, MD

Two doctors discussing zanidatamab-based treatment options for HER2-positive gastric cancer against a city skyline background.

Conferences

06/10/2026

HERIZON-GEA-01 Updates and Sequencing HER2-Directed Treatments in Gastric Cancer

Geoffrey Ku, MDSteven Maron, MD, MSc

Two medical professionals, Joseph McCollom, DO, and Rachna Shroff, MD, MS, FASCO, discuss the latest updates on upper gastrointestinal cancer care at the Matterhorn conference.

Conferences

06/09/2026

GI Oncologists Discuss MATTERHORN Updates and Challenging HCC Subgroups

Joseph McCollom, DORachna Shroff, MD, MS, FASCO

Conferences

06/09/2026

The Current Paradigm for Selecting and Sequencing ADCs in Metastatic TNBC

Alexis Levee, MDHope Rugo, MD, FASCO

Conferences

06/09/2026

Experts Review Groundbreaking Data From RASolute 302 and Its Impact on GI Oncology

Charbel Matar, MDDeepak Vadehra, DO

Conferences

06/09/2026

Key ASCO 2026 Updates in NSCLC and SCLC

Chinmay Jani, MDTessa Lavorgna, MD

Two medical professionals, Dr. Rohit Gosain and Dr. Danai Dima, discuss CAR-T therapy for multiple myeloma in an urban cityscape background.

Conferences

06/08/2026

How Community Oncologists Can Optimize CAR T-Cell Therapy for Patients With Multiple Myeloma

Danai Dima, MDRohit Gosain, MD

Conferences

06/08/2026

Doctors React to the New Treatment Landscape for Gastric and Gastroesophageal Junction Cancers

Charbel Matar, MDRaji Shameem, MD

Conferences

06/08/2026

How to Select a CDK4/6 Inhibitor in Early or Metastatic Breast Cancer

Giuseppe Curigliano, MD, PhDArya Mariam Roy, MD

Two female doctors, Sarah Premji, MD, and Komal Jhaveri, MD, FACP, discussing biomarker testing for HR-positive metastatic breast cancer against a city skyline background.

Conferences

06/07/2026

Biomarker Testing and Targeted Therapy Advancements in Metastatic Breast Cancer

Komal Jhaveri, MD, FACPSarah Premji, MD

Zanidatamab emerging as a potential new standard of care in oncology, featuring Dr. Shruti Patel and Dr. Tanios Bekaii-Saab discussing innovative cancer treatment options.

Conferences

06/07/2026

Transformational Data From HERIZON-GEA-01 and RASolute 302 for GI Malignances

Tanios Bekaii-Saab, MDShruti Patel, MD

Conferences

06/07/2026

Insights From ASCO 2026: Evolving Treatment Strategies in Gastrointestinal Malignancies

Aslihan Yerlikaya, MD

OncUpdates episode featuring discussions on bringing Mezidomide into clinical practice, focusing on efficacy, safety, and implications for oncology treatment.

Conferences

06/07/2026

Bringing Mezigdomide Into Practice: Efficacy, Safety, and Clinical Implications

Paul G. Richardson, MDRahul Gosain, MD, MBA

Expert discussion on Mezidomide's mechanism of action and early clinical development, featuring Rahul Gosain and Paul Richardson.

Conferences

06/07/2026

Understanding Mezigdomide: Mechanism of Action and Early Clinical Development

Paul G. Richardson, MDRahul Gosain, MD, MBA

Experts Christine Garcia, MD, MPH, and Rami Manoachakian, MD, discuss innovative small cell lung cancer treatments in a city skyline setting.

Conferences

06/06/2026

Oncologists Highlight Tarlatamab and Other Advancements in SCLC

Chirstine Garcia, MD, MPHRami Manochakian, MD

Conferences

06/06/2026

The Impact of EV Trials Across Bladder Cancer Populations

Andrea B. Apolo, MDElias Chandran, MBBS, FRACP

Conferences

06/03/2026

Rapid Reactions: Expanding Treatment Options in Relapsed/Refractory Multiple Myeloma

Paul G. Richardson, MDRahul Gosain, MD, MBA

Key updates from ESMO Breast Cancer 2026, featuring Dr. Rahul Gosain, Dr. Rohit Gosain, and Dr. Erika Hamilton discussing recent advances in breast cancer trials.

Conferences

05/29/2026

Six Major Trial Updates From ESMO Breast Cancer 2026

Erika Hamilton, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Conferences

05/28/2026

What to Watch at ASCO 2026: A Thoracic Oncologist’s Guide to the Lung Cancer Program

Dan Morgenstern, MDChinmay Jani, MDGilberto Lopes, MD

Modern metallic sculpture in an urban setting with skyscrapers, promoting the ASCO 2026 gastrointestinal cancer conference and research updates.

Conferences

05/15/2026

ASCO 2026: Gastrointestinal Abstracts to Watch

Raji Shameem, MD

Advanced medical professionals discussing bladder, kidney, and prostate cancer updates at ASCO GU 2026 conference.

Conferences

03/25/2026

Bladder, Kidney, and Prostate Cancer Highlights From ASCO GU 2026

Petros Grivas, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Conferences

03/20/2026

ASCO GU 2026: Key Updates in Bladder, Prostate, and Kidney Cancer

Charbel Matar, MD

Advanced renal cell carcinoma research on HIF-2α inhibition featuring Dr. Michael Serzan and Dr. Toni Choueiri, with a cityscape background, highlighting innovative cancer treatment developments.

Conferences

03/16/2026

Positive Trials for Belzutifan in Earlier Treatment Lines for RCC

Michael Serzan, MDToni Choueiri, MD

EV Plus Pembrolizumab and Systemic Therapy Advances in GU Oncology - OncUpdates.

Conferences

03/16/2026

Community Takeaways From ASCO GU 2026

Regina Barragan-Carrillo, MDRaji Shameem, MD

Conferences

03/16/2026

ASCO GU 2026: Experts Highlight Key Updates in Prostate Cancer

Brooke Kania, DOSindhuja Kadambi, MD, MS

Postoperative radiation and personalized therapy in GU cancers, featuring two smiling female doctors against a cityscape background.

Conferences

03/16/2026

A Personalized Approach to Treating GU Cancers

Sophia Kamran, MDNatalie Reizine, MD

Conferences

03/15/2026

Novel HER2–Targeting Therapies in Urothelial Cancer

Miles Hsu, MDBrendan Guercio, MD

Radiotherapy strategies in metastatic clear cell renal cell carcinoma featuring Dr. Shreyas Kalantri and Dr. Michael Serzan with a cityscape background.

Conferences

03/15/2026

Radiotherapy Strategies in Metastatic Clear Cell Renal Cell Carcinoma

Michael Serzan, MDShreyas Kalantri, MD

Advanced medical professionals discussing Radium-223 Plus Enzalutamide in mCRPC with bone metastases in an urban hospital setting.

Conferences

03/14/2026

PEACE-3 OS Data Support Radium-223 Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Sindhuja Kadambi, MD, MSKarine Tawagi, MD

Conferences

03/13/2026

Circulating Tumor DNA to Guide Treatment in Muscle-Invasive Bladder Cancer

Brendan Guercio, MDAndrea B. Apolo, MD

ASCO GU 2026 conference banner highlighting novel therapies transforming genitourinary oncology, featuring the Golden Gate Bridge in San Francisco.

Conferences

03/13/2026

ASCO GU 2026: Novel Therapies Transform Genitourinary Oncology

Manas Pustake, MD

Enhanced cancer treatment research featuring Dr. Nicholas Simon and Dr. Sumanta Pal discussing Cabozantinib and novel doublets in advanced renal cell carcinoma.

Conferences

03/12/2026

Cabozantinib and Novel Doublets in Advanced RCC

Nicholas Simon, MDSumanta Pal, MD, FASCO

Conferences

03/12/2026

First-Line Treatment Strategies in Metastatic Renal Cell Carcinoma

Andre Kydd, MD, PhDNicholas Simon, MD

PARP inhibitor combination therapy in metastatic prostate cancer, featuring Jeffrey Zhong, MD, and Karan Jatwani, MD, with a cityscape background.

Conferences

03/11/2026

PARP Inhibitor Combination Therapy in Metastatic Prostate Cancer

Karan Jatwani, MDJeffrey Zhong, MD

EV Plus Pembro improves outcomes in muscle-invasive bladder cancer in KEYNOTE-B15/EV-304, featuring researchers Rohit Gosain, MD, and Rahul Gosain, MD, MBA, with a cityscape background.

Conferences

03/10/2026

Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Muscle-Invasive Bladder Cancer in KEYNOTE-B15/EV-304

Rahul Gosain, MD, MBARohit Gosain, MD

Efficacy of Enfortumab Vedotin and Pembrolizumab in muscle-invasive bladder cancer treatment, featuring experts Elias Chandran and Vishesh Khanna against a cityscape background.

Conferences

03/09/2026

Enfortumab Vedotin-Pembrolizumab’s Role in Muscle-Invasive Bladder Cancer Treatment

Elias Chandran, MBBS, FRACPVishesh Khanna, MD

Evolving treatment strategies in bladder cancer research presented by OncUpdates, featuring medical professionals discussing innovative therapies and recent advancements in bladder cancer management.

Conferences

03/09/2026

Insights from ASCO GU 2026: Evolving Treatment Strategies in Bladder Cancer

Zeynep Irem Ozay, MD

Conferences

03/08/2026

Immunotherapy Plus BCG Shows Promise in NMIBC: Insights From POTOMAC and CREST

Ashish M. Kamat, MD, MBBS, FACSVishesh Khanna, MD

Conferences

03/06/2026

Capivasertib Plus Abiraterone in Metastatic Prostate Cancer

Alan Bryce, MDKaran Jatwani, MD

Conferences

03/05/2026

Evolving Standards in Renal Cell Carcinoma: Practical Insights from ASCO GU

Adriana Penate, MD

Dr. Rebecca Shatsky discusses clinical trials on adjuvant carboplatin and PARP inhibitors in triple-negative breast cancer (TNBC) at OncUpdates.

Conferences

03/05/2026

Adjuvant Carboplatin and PARP Inhibitor Combination Trials in TNBC

Rebecca Shatsky, MDRahul Gosain, MD, MBARohit Gosain, MD

An image of Dr. Jorge Cortes presenting AML and CML highlights from ASH 2025, featuring Dr. Rahul Gosain and Dr. Rohit Gosain, with a professional background related to hematology and oncology researc.

Conferences

03/04/2026

AML and CML Highlights From ASH 2025

Jorge Cortes, MDRahul Gosain, MD, MBARohit Gosain, MD

Bispecifics, BTK inhibitors, and immunotherapy advances in lymphoma treatment, featuring experts Dr. Rahul Gosain, Dr. Julie Vose, and Dr. Rohit Gosain at OncUpdates conference.

Conferences

02/26/2026

Bispecifics, BTK Inhibitors, and Immunotherapy Drive Lymphoma Advances

Conferences

02/04/2026

Updating Care Models for Patients With Early-Onset GI Cancer

Youssef Bouferraa, MDShruti Patel, MD

1. Expert discussion on preventing chemotherapy toxicity and the importance of universal DPYD testing for cancer patients.

Conferences

02/03/2026

FDA Update Reflects Need for Genetic Testing Prior to Capecitabine

Conferences

01/22/2026

Expert Perspectives on the BREAKWATER Trial in Metastatic Colorectal Cancer

Daniel Tuerff, MDNicholas Hornstein, MD, PhD

1. Expert panelists Dr. Rohit Gosain, Dr. Rachna Shroff, and Dr. Rahul Gosain discuss key insights on gastrointestinal cancers at the 2026 ASCO Gastrointestinal Cancers Symposium.

Conferences

01/22/2026

4 Key Abstracts from the 2026 ASCO Gastrointestinal Cancers Symposium

Rachna Shroff, MD, MS, FASCORahul Gosain, MD, MBARohit Gosain, MD

Conferences

01/21/2026

CABINET and STELLAR-303 Trials Inform Treatment in NETs and mCRC

Nicholas Hornstein, MD, PhDAnwaar Saeed, MD

Pancreatic cancer biomarker testing and clinical decision-making, patient-centered care seminar featuring Fiyinfolu Balogun MD PhD and Wungki Park MD MS in front of a cityscape with a bridge at sunset.

Conferences

01/19/2026

ASCO GI 2026: Precision Medicine Gains Momentum in Pancreatic Cancer

Fiyinfolu Balogun, MD, PhDWungki Park, MD, MS

KRAS inhibitors, targeted therapy, GI oncology, cancer treatment, molecular targeted therapy, cancer research, precision medicine, oncology advancements, clinical oncology, cancer therapy innovation.

Conferences

01/19/2026

Molecular Profiling Expands Treatment Options in Pancreatic and Biliary Tract Cancers

Dina Ioffe, MDShubham Pant, MD, MBBS

1. Hands holding a pink ribbon symbolizing breast cancer awareness on a gray background.

Conferences

01/17/2026

From ADCs to Oral SERDs: Practice-Changing Insights from SABCS 2025

Zunairah Shah, MD

Conferences

01/17/2026

Impact of ADCs in Early TNBC Treatment

Mariam Haji Ahmad, MBBChAlexis Levee, MD

Azacitidine and venetoclax combination therapy for AML, showcasing practice-changing insights from ASH 2025 presented by Jayastu Senapati and Uma Borate.

Conferences

01/16/2026

Azacitidine in AML: Key Takeaways From the PARADIGM Study

Jayastu Senapati, MBBSUma Borate, MBBS

Multimodal image featuring two doctors discussing cellular therapy for multiple myeloma, with cityscape background, emphasizing oncology research, CAR T-cell therapy, bispecific antibodies, and personalized cancer care advancements.

Conferences

01/16/2026

Collaboration is Key to Safely Transition Care in MM Following Cellular Therapy

Hamza Hashmi, MDShreyas Kalantri, MD

Conferences

01/15/2026

Insights on CAR-NK Therapy and Hodgkin Lymphoma Updates at ASH 2025

Sam Yamshon, MDAndrew M. Evens, DO, MBA, MSc

Antibody-drug conjugates reshaping triple-negative breast cancer treatment algorithm, oncologists discuss advances.

Conferences

01/15/2026

ADCs in TNBC: Current Data and Unanswered Questions

Pietro De Placido, MDDionisia Quiroga, DO, PhD

Inovative breast cancer research and treatment insights from OncUpdates, featuring experts Tyler Kristoff, MD, and Sarah Premji, MD, focusing on the role of Inavolisib as a first-line therapy and emerging oral SERDs.

Conferences

01/13/2026

SABCS 2025 Updates on Inavolisib and Giredestrant in Breast Cancer

Tyler Kristoff, MDSarah Premji, MD

1. Expert oncologists Kingsley Nnawuba and Urshila Durani discuss advancements in lymphoma treatment, including ESMO guidelines, immunotherapy, and combination therapies for improved patient outcomes.

Conferences

01/13/2026

Oncologists Review Practice-Changing Lymphoma Findings From ASH 2025

Kingsley Nnawuba, MDUrshila Durani, MD, MPH

1. In-depth analysis of HR+ and early breast cancer studies from SABCS 2025 featuring experts Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Laura Huppert.

Conferences

01/12/2026

Key HR+, Early Breast Cancer Abstracts From SABCS 2025

Laura Huppert, MDRahul Gosain, MD, MBARohit Gosain, MD

Blood sample in a test tube with laboratory report background, highlighting hematology and oncology research.

Conferences

01/11/2026

Key Studies Shaping Hematology, Community Oncology at ASH 2025

Sawyer Bawek, DO

Conferences

01/08/2026

Early Intervention Strategies in High-Risk Smoldering Multiple Myeloma

Anuja V. Abhyankar, MDJing Wang, MD

Enhanced medical research on hematology and oncology at ASH 2025 conference with clinical laboratory professionals.

Conferences

01/07/2026

ASH 2025 Breakthroughs: Key Studies Shaping Hematology and Community Oncology

Sawyer Bawek, DO

HER2-positive breast cancer research update featuring Yash Agrawal, MD, and Stephanie Graff, MD, discussing 2025 advancements in DESTINY trials and beyond for improved breast cancer therapies.

Conferences

01/05/2026

The Evolving Role of T-DXd Across HER2+ Breast Cancer

Yash Agrawal, MDStephanie Graff, MD, FACP, FASCO

1. Female healthcare professionals discussing breast cancer prevention and patient advocacy for cancer care education and empowerment.

Conferences

01/04/2026

Patient Advocacy Brings Breast Cancer Vaccine to Phase 1 Trial

Judy FitzgeraldKarissa Britten, MD

$1. Researchers and clinicians discuss strategies for managing lenalidomide, CD38, and multi-refractory disease in relapsed multiple myeloma treatment at OncUpdates conference.$

Conferences

01/04/2026

How to Select Treatment in Relapsed Multiple Myeloma

Anuja V. Abhyankar, MDS. Vincent Rajkumar, MD

Early use of bispecific antibodies and CAR T strategies in relapsed multiple myeloma, discussed by experts Hamza Hashmi, MD, and Robert Orlowski, MD, PhD, with a cityscape background.

Conferences

01/03/2026

Bispecific Antibodies and CAR T Redefine Early-Line Treatment in Multiple Myeloma

Robert Orlowski, MD, PhDHamza Hashmi, MD

Enhanced image of two medical professionals discussing CDK4/6 inhibitors for cancer treatment at OncUpdates, with a cityscape background highlighting expertise in oncology research and therapy options.

Conferences

01/02/2026

NATALEE 5-Year IDFS Data at SABCS 2025

Matthew Kurian, MDJasmin Hundal, MD

Conferences

01/01/2026

Anti-TROP-2 ADCs in PD-L1-Negative TNBC

Conferences

12/26/2025

SABCS 2025: HER2CLIMB-05 and DESTINY Trials Point to More Individualized Care in HER2-Positive Breast Cancer

Nerea Lopetegui-Lia, MDSusan Dent, BSc, MD

Accelerating breast cancer treatment research by integrating Sacituzumab govitecan, Pembrolizumab, with expert clinicians Dionisia Quiroga, DO, PhD, and Erika Hamilton, MD, in Las Vegas skyline background.

Conferences

12/25/2025

SABCS 2025: Clarifying Where Sacituzumab Govitecan Fits in the Breast Cancer Treatment Landscape

Erika Hamilton, MD, FASCODionisia Quiroga, DO, PhD

Conferences

12/24/2025

Reviewing ASH 2025 Data for ALL and TP53-Mutated AML or MDS

Abhishek Maiti, MDMycal Casey, DO

1. Advanced blood cancer cells including leukemia, lymphoma, myeloma, and chronic lymphocytic leukemia (CLL).

Conferences

12/24/2025

CLL, AML, Lymphoma, and Myeloma Updates Poised to Impact Clinical Practice

Valentina Ardila Avila, MD

1. Expert oncologists discussing treatment options for cancer, emphasizing Venetoclax-based regimens, targeted agents, and rapid molecular profiling for personalized therapy.

Conferences

12/23/2025

Improving Venetoclax and Other Targeted Therapies in AML

Zachary Braunstein, MDJayastu Senapati, MBBS

Enhanced leukemia research and advancements discussed at ASH 2025, offering expert insights and future directions in hematologic cancer treatment from renowned specialists.

Conferences

12/23/2025

Leukemia Advances at ASH 2025: Expert Insights and Future Directions

Niranjan Khaire, MBBS, MD, DM

Advanced personalized chemotherapy strategies for chronic lymphocytic leukemia based on ASH 2025 guidelines. Expert insights by Lauren M. Granat, DO, MS, on targeted cancer therapies.

Conferences

12/22/2025

ASH 2025 Signals Shift Toward Personalized, Time-Limited Therapy in Chronic Lymphocytic Leukemia

Lauren M. Granat, DO, MS

Adjuvant CDK4/6 inhibition in early breast cancer discussed by renowned experts Matthew Kurian and Komal Jhaveri at OncUpdates.

Conferences

12/21/2025

NATALEE and Other Updates for HR+ Early Breast Cancer at SABCS 2025

Komal Jhaveri, MD, FACPMatthew Kurian, MD

Conferences

12/20/2025

Experts Discuss Sonrotoclax and Lymphoma Trials at ASH 2025

Agrima Mian, MDSam Yamshon, MD

Conferences

12/20/2025

Ibrutinib Updates in CLL From ASH 2025

Mahesh Swaminathan, MB, MSVanthana Bharthi, MD

Conferences

12/19/2025

Evolving Treatment Paradigms in Advanced Breast Cancer: Key Trial Updates From SABCS 2025

Karissa Britten, MDVaishali Deenadayalan, MD

1. Advances in early-stage breast cancer treatment focusing on CDK4/6 inhibitors for adjuvant therapy.

Conferences

12/19/2025

Key Insights From the NATALEE Trial

Karissa Britten, MDMatthew Kurian, MD

Conferences

12/19/2025

Evolving Approaches to Early-Stage and Metastatic TNBC

Briana To, DO, PhD

1. AlT text: Expert discussion on managing breast cancer relapse with adjuvant CDK4/6 inhibitor therapy in ER-positive cases, featuring Dr. Sarah Premji and Dr. Kevin Kalinsky.

Conferences

12/18/2025

SABCS 2025: Evolving Role of CDK4/6 Inhibitors and SERDs in ER-Positive Breast Cancer

Kevin Kalinsky, MD, MS, FASCOSarah Premji, MD

Conferences

12/18/2025

Breaking Down ASH 2025 Data on Frontline Pirtobrutinib in CLL

Bita Fakhri, MD, MPHMahesh Swaminathan, MB, MS

Conferences

12/18/2025

Sequencing BTKi Therapies in Patients With CLL

Claudia Villa Celi, MDDaniel Ermann, MD

Conferences

12/17/2025

SEQUOIA Trial Long-Term Data Support Second-Generation BTK Inhibitors in CLL

Catherine Coombs, MDDaniel Ermann, MD

Imaging for oncological research on follicular lymphoma, featuring MDs Urshila Durani and Joshua Brody, highlighting practice-changing data from EPCORE FL-1 clinical trial in a skyline cityscape background.

Conferences

12/17/2025

Primary Results From EPCORE FL-1 Presented at ASH 2025

Urshila Durani, MD, MPHJoshua Brody, MD

1. New research data on lymphoma care presented at ASH 2025, emphasizing advances from frontline treatment to relapse management.

Conferences

12/14/2025

New Data at ASH 2025 Reshapes Lymphoma Care From Frontline to Relapsed Disease

Rafaella Litvin, MD

1. Medical professional analyzing lung cancer CT scan highlighting tumor with red laser pointer, illustrating cancer diagnosis and screening.

Conferences

11/25/2025

Revolutionizing Treatment for EGFR-Mutated NSCLC

Coral Olazagasti, MD

Conferences

11/17/2025

Dual Targeting: Iza-bren Shows Promising Early Results Across Solid Tumors

Samantha El Warrak, MBBSChinmay Jani, MD

Conferences

11/14/2025

PALOMA-2: Subcutaneous Amivantamab Plus Lazertinib Delivers MARIPOSA-Level Efficacy with Improved Safety

Akshee Batra, MDChinmay Jani, MD

Conferences

11/13/2025

DLL3-Targeted Antibody-Drug Conjugate Reignites Hope for Relapsed SCLC

Conferences

10/30/2025

ESMO 2025: Updates in Bladder Cancer

Vishesh Khanna, MD

Electronic health records consultation with healthcare professional discussing cancer treatment options.

Conferences

10/28/2025

ESMO 2025 Breaking New Ground in Breast Cancer: Five Trials to Know

Matthew Kurian, MD

Vibrant scientific laboratory scene with test tubes and a pipette, showcasing advanced cancer research and clinical trials, highlighting oncology innovations and medical breakthroughs in cancer treatment.

Conferences

10/25/2025

ESMO 2025: Updated Results From the monarchE Trial in Early Breast Cancer

Sarah Premji, MDMatthew Goetz, MD

Microscopic view of cancer cells, illustrating cellular structures and tumor development for oncology research and cancer treatment insights.

Conferences

10/24/2025

Key Updates in Gastrointestinal Oncology from ESMO 2025

Udhayvir Singh Grewal, MD

Berlin cityscape at dusk with the TV Tower, historic buildings, and river, highlighting oncology research and medical innovation in Germany for oncology updates and cancer treatment advancements.

Conferences

10/17/2025

The 12 Most Anticipated Practice-Changing Abstracts at ESMO 2025: Community Oncologist’s Guide

Conferences

07/02/2025

Breakthroughs in Bladder, Prostate, and Kidney Cancer: What Oncologists Need to Know From ASCO 2025

Saad Atiq, MD

Conferences

06/30/2025

Durvalumab Enters the Perioperative Landscape in Muscle-Invasive Bladder Cancer: Reflections from the NIAGARA Trial and ASCO 2025 Updates

Charbel Matar, MD

Conferences

06/27/2025

Five Major Colorectal and GI Cancer Abstracts From 2025 ASCO

Rahul Gosain, MD, MBARohit Gosain, MDCathy Eng, MD, FACP, FASCO

Conferences

06/11/2025

Clinical Impact of DESTINY-Breast09 in HER2+ Breast Cancer Management

Arya Mariam Roy, MDHope Rugo, MD, FASCO

Innovative oncology conference with experts discussing advancements in cancer treatment and research in a modern, well-lit venue.

Conferences

06/11/2025

Small Cell Lung Cancer Takes Center Stage at ASCO 2025

Eric Singhi, MDSandip Patel, MD, FASCO

Advances in oncology, cancer research, and breakthrough treatments discussed at an oncology conference with medical professionals.

Conferences

06/11/2025

Strategic Timing for Multidisciplinary Care in Breast Cancer

Jasmin Hundal, MDMatthew Kurian, MD

Innovative oncology discussion at OncUpdates conference focused on advancements in cancer treatment and care. Two experts sharing insights on future oncology practices at the event.

Conferences

06/11/2025

ASCO 2025: Key Clinical Trials in Resectable NSCLC

Eric Singhi, MDMitchell Alexander Parma, MD

Conferences

06/11/2025

Tailoring Treatment for Patients With EGFR-Positive NSCLC

Chinmay Jani, MDCoral Olazagasti, MD

Conferences

06/11/2025

New Questions in Muscle-Invasive Bladder Cancer After the NIAGARA Trial

Albert Jang, MDMichael Serzan, MD

Conferences

06/11/2025

Highlights From the AMPLITUDE Study at ASCO 2025

Albert Jang, MDMichael Serzan, MD

Conferences

06/11/2025

Updated CheckMate 214 Results Support Ipi-Nivo for Favorable-Risk Kidney Cancer

Albert Jang, MDMichael Serzan, MD

Data for tomorrow’s oncology practice and research, oncological innovations, cancer treatment advancements, and cancer research updates at OncUpdates.

Conferences

06/11/2025

MATTERHORN Trial: Promising Results and Unanswered Questions

Deepak Vadehra, DOSupriya Peshin, MD

Innovative oncology research discussion at OncUpdates conference, focusing on advancements in cancer treatment, personalized medicine, and new therapies in oncology.

Conferences

06/11/2025

Diverse Bispecific Strategies Emerging Across GI Cancers

Shruti Patel, MDUdhayvir Singh Grewal, MD

Two women engaged in a discussion on stage at the ASCO 2025 oncology conference, with a backdrop of plants and modern decor.

Conferences

06/11/2025

Advancements in Oncology at ASCO 2025: Breast Cancer Highlights

Tanmayi Pai, MD

High-quality healthcare professional woman speaking at oncology conference, discussing cancer treatment updates, in a comfortable, modern setting with natural lighting and stylish decor.

Conferences

06/10/2025

Key Takeaways From ASCO 2025 for Hormone-Receptor+ Metastatic Breast Cancer

Komal Jhaveri, MD, FACPMatthew Kurian, MD

Conferences

06/10/2025

Integrating Metastatic Triple-Negative Breast Cancer NCCN Guidelines Into Clinical Practice

Arya Mariam Roy, MDHope Rugo, MD, FASCO

Conferences

06/10/2025

ASCENT-04 Trial: First-Line Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1+ TNBC

Arya Mariam Roy, MDHope Rugo, MD, FASCO

Conferences

06/10/2025

Lurbinectedin Offers Significant Survival Benefit for Patients With Extensive-Stage SCLC

Innovative medical conference with healthcare professionals discussing oncology treatments and latest cancer research advancements in a modern venue.

Conferences

05/23/2025

Advances in Managing CNS Metastases in Breast Cancer: SABCS 2024 Insights

Hetal Mistry, MD

Coral Olazagasti, MD

View All

Coral Olazagasti, MD

06/17/2026

From Resistance to Response: Amivantamab Opens a New Chapter in Head and Neck Cancer

Coral Olazagasti, MD

11/25/2025

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

Danny Nguyen, MD

Ulka Vaishampayan, MBBSDavid Braun, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

David Braun, MD, PhD

12/06/2025

Treating Advanced RCC After First-Line Therapy (Full Video)

David Braun, MD, PhDBradley McGregor, MDUlka Vaishampayan, MBBSRahul Gosain, MD, MBARohit Gosain, MD

$Because I can't access external links or view images, I can't analyze the specific image from the URL provided. However, based on the description and context related to "OncUpdates" and the title "Selecting Treatments for Cases in Relapsed or Refractory RCC," I can generate SEO-optimized text for a typical promotional or informational medical image related to this topic.$

David Braun, MD, PhD

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD

Deepa Rangachari, MD

View All

Early stage non-small cell lung cancer treatment updates 2025 featuring Dr. Deepa Rangachari, Dr. Rohit Gosain, and Dr. Rahul Gosain for oncology professionals and patients.

Deepa Rangachari, MD

Ep. 3: Clinical Insights: Escalation vs De-escalation in EGFR-Positive NSCLC

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

Edgardo Santos Castillero, MD, FACP, FASCO

12/21/2025

Ep. 2: CNS Control and Resistance: Panel Examines Amivantamab Plus Lazertinib

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

Edgardo Santos Castillero, MD, FACP, FASCO

12/19/2025

Ep. 1: Overall Survival Updates in EGFR-Positive NSCLC: MARIPOSA and FLAURA2

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

Edgardo Santos Castillero, MD, FACP, FASCO

Sara Hurvitz, MD, FACPSherry Shen, MDEleonora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD

Eleonora Teplinsky, MD

12/20/2025

Adjuvant Ribociclib and Abemaciclib in Early HR+ Breast Cancer (Full Video)

Eleonora Teplinsky, MDSara Hurvitz, MD, FACPSherry Shen, MDRahul Gosain, MD, MBARohit Gosain, MD

Elia Segui Solis, MD

View All

Elia Segui Solis, MD

12/29/2025

SABCS 2025: Expert Perspective on CDK4/6 Inhibitor Use in Metastatic Hormone Receptor-Positive Breast Cancer

Matthew Kurian, MDElia Segui Solis, MD

Elias Chandran, MBBS, FRACP

View All

Elias Chandran, MBBS, FRACP

06/06/2026

The Impact of EV Trials Across Bladder Cancer Populations

Andrea B. Apolo, MDElias Chandran, MBBS, FRACP

Elias Chandran, MBBS, FRACP

03/09/2026

Enfortumab Vedotin-Pembrolizumab’s Role in Muscle-Invasive Bladder Cancer Treatment

Elias Chandran, MBBS, FRACPVishesh Khanna, MD

Emily Gallagher, MD, PhD

View All

Toxicity check for PI3K/AKT inhibitor side effects in metastatic breast cancer with experts Dr. Emily Gallagher and Dr. Neil Iyengar.

Emily Gallagher, MD, PhD

01/06/2026

PI3K/AKT Inhibitor Side Effect Management in Metastatic Breast Cancer

Emily Gallagher, MD, PhDNeil Iyengar, MDRohit Gosain, MDRahul Gosain, MD, MBA

Enrique Grande, MD, PhD, MSC

View All

Enrique Grande, MD, PhD, MSC

06/10/2025

Second-Line Treatment Sequencing in Metastatic RCC

Enrique Grande, MD, PhD, MSCKaran Jatwani, MD

Eric Singhi, MD

View All

Dr. Eric Singhi smiling in a professional portrait, with two other doctors discussing targeted therapies for metastatic non-small cell lung cancer (NSCLC) with actionable mutations.

Joshua Sabari, MDAlexander Spira, MD, PhD, FACP, FASCODanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MD

Eric Singhi, MD

10/20/2025

Treating Complex Cases of EGFR-Mutated NSCLC

Eric Singhi, MDRahul Gosain, MD, MBARohit Gosain, MD

Eric Singhi, MD

06/11/2025

Small Cell Lung Cancer Takes Center Stage at ASCO 2025

Eric Singhi, MDSandip Patel, MD, FASCO

Eric Singhi, MD

06/11/2025

ASCO 2025: Key Clinical Trials in Resectable NSCLC

Eric Singhi, MDMitchell Alexander Parma, MD

Eric Singhi, MD

06/10/2025

Lurbinectedin Offers Significant Survival Benefit for Patients With Extensive-Stage SCLC

Eric Singhi, MDSandip Patel, MD, FASCO

Erica Mayer, MD, MPH

View All

Experts discussing treatment options for ESR1-mutated metastatic breast cancer, focusing on switching to Camizestrant before progression.

Erica Mayer, MD, MPH

09/22/2026

Switching to Camizestrant Before Progression in ESR1–Mutated Metastatic Breast Cancer

Erica Mayer, MD, MPHRahul Gosain, MD, MBARohit Gosain, MD

Evolving treatment algorithms for early-stage hormone receptor-positive breast cancer research by Dr. Erica Mayer and colleagues.

Erica Mayer, MD, MPH

Estelamari Rodriguez, MD, MPH

11/15/2025

Optimizing ROS1 Inhibitor Therapy in NSCLC

Estelamari Rodriguez, MD, MPHRohit Gosain, MDRahul Gosain, MD, MBA

Estelamari Rodriguez, MD, MPH

11/12/2025

Chemotherapy Plus Osimertinib Offers Overall Survival Benefit in EGFR-mutated NSCLC

Daniel Tuerff, MDChinmay Jani, MDEstelamari Rodriguez, MD, MPH

Estelamari Rodriguez, MD, MPH

06/16/2025

Ep. 3: How to Choose the Best First-Line Therapy for Patients With EGFR-Mutated NSCLC

Susan Scott, MDEstelamari Rodriguez, MD, MPHHelena Yu, MD

Estelamari Rodriguez, MD, MPH

06/16/2025

EP. 1: Targeted Therapies in EGFR-Mutated NSCLC: Managing Treatment-Related AEs

Fadi Haddad, MDHagop Kantarjian, MD

Dr. Fadi Haddad, Dr. Gabriela Hobbs, Dr. Rohit Gosain, and Dr. Rahul Gosain discuss challenging oncology cases, including frontline TKI for CML and treatment options.

Fadi Haddad, MD

05/25/2026

Challenging Cases: Frontline TKI for CML and Options Upon Progression

Fadi Haddad, MDGabriela Hobbs, MDRahul Gosain, MD, MBARohit Gosain, MD

Fadi Haddad, MD

12/31/2025

ASH 2025 CML Highlights: Asciminib, Ponatinib Optimization, and Treatment Sequencing

Sawyer Bawek, DOFadi Haddad, MD

Toxicity management in cancer treatment, featuring experts Dr. Fadi Haddad, Dr. Onyee Chan, Dr. Rahul Gosain, and Dr. Rohit Gosain, discussing side effects of Tyrosine Kinase Inhibitors in CML.

Fadi Haddad, MD

11/11/2025

How to Manage Side Effects of Tyrosine Kinase Inhibitors in CML

Fadi Haddad, MDOnyee Chan, MDRahul Gosain, MD, MBARohit Gosain, MD

Fangdi Sun, MD

View All

Fangdi Sun, MD

06/13/2026

Emerging Data on Amivantamab and Other Anti-EGFR Bispecifics in Head and Neck Cancer

Nicole Dalal, MDFangdi Sun, MD

A woman smiling, representing Dr. Fangdi Sun, with a green background and text about current treatment pathways for head and neck cancers.

Fangdi Sun, MD

02/17/2026

The Current Treatment Pathways for Head and Neck Cancers

Fangdi Sun, MDRahul Gosain, MD, MBARohit Gosain, MD

Fawzi Abu Rous, MD

View All

Fawzi Abu Rous, MD

03/19/2026

Ep. 3: Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC

Eric Singhi, MDSarah Goldberg, MD, MPHFawzi Abu Rous, MDJulia Rotow, MDSusan Scott, MD

Fawzi Abu Rous, MD

03/17/2026

Ep. 2: Clinical Insights: Proactive Toxicity Management and CNS Control in EGFR-Mutant NSCLC

Eric Singhi, MDSarah Goldberg, MD, MPHSusan Scott, MDFawzi Abu Rous, MDJulia Rotow, MD

Fawzi Abu Rous, MD

03/14/2026

Ep. 1: OS Benefit and Patient-Centered Delivery Advances in EGFR-Mutant NSCLC

Eric Singhi, MDSusan Scott, MDSarah Goldberg, MD, MPHFawzi Abu Rous, MDJulia Rotow, MD

Fiyinfolu Balogun, MD, PhD

View All

Fiyinfolu Balogun, MD, PhD

01/23/2026

Pancreatic Cancer Highlights From ASCO GI 2026

Fiyinfolu Balogun, MD, PhDAngelo Pirozzi, MD

Fiyinfolu Balogun, MD, PhD

Rahul Gosain, MD, MBARohit Gosain, MDGeoffrey Ku, MDRutika Mehta, MD, MB, MPHManish Shah, MDNataliya Uboha, MD, PhD

Geoffrey Ku, MD

01/20/2026

HERIZON-GEA-01: Zanidatamab for HER2+ Advanced Gastroesophageal Cancer

Rahul Gosain, MD, MBARohit Gosain, MDGeoffrey Ku, MDRutika Mehta, MD, MB, MPHManish Shah, MDNataliya Uboha, MD, PhD

Gilberto Lopes, MD

View All

Gilberto Lopes, MD

09/25/2026

CROWN at 7 Years: A New Benchmark for Durable Disease Control in ALK-Positive NSCLC

Diya JayramChinmay Jani, MDGilberto Lopes, MD

Gilberto Lopes, MD

05/28/2026

What to Watch at ASCO 2026: A Thoracic Oncologist’s Guide to the Lung Cancer Program

Dan Morgenstern, MDChinmay Jani, MDGilberto Lopes, MD

Gilberto Lopes, MD

05/18/2026

Beyond Osimertinib Monotherapy: Frontline Intensification in EGFR-Mutant NSCLC After FLAURA2 and MARIPOSA

Chinmay Jani, MDRuchi JaniGilberto Lopes, MD

Gilberto Lopes, MD

01/25/2026

Top Lung Cancer Advances From 2025

Chinmay Jani, MDAli Al Sbihi, MDGilberto Lopes, MD

Expert panel discussing management of anti-EGFR toxicities in NSCLC treatment strategies.

Gilberto Lopes, MD

05/28/2025

How to Manage Anti-EGFR Toxicities in NSCLC

Gilberto Lopes, MD

Gilles Salles, MD, PhD

View All

Medical conference image featuring Dr. Matthew Lunning, Dr. Gilles Salles, Dr. Rohit Gosain, and Dr. Rahul Gosain discussing challenging DLBCL cases.

Gilles Salles, MD, PhD

07/30/2026

Challenging DLBCL Cases: Early Relapse and Follicular Lymphoma Transformation

Matthew Lunning, DO, FACPGilles Salles, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

EPCORE FL-1 trial discussing Epcoritamab, Lenalidomide, and Rituximab for follicular lymphoma, featuring Dr. Giles Salles, Dr. Rahul Gosain, and Dr. Rohit Gosain, highlighting advancements in lymphoma treatment and research.

Gilles Salles, MD, PhD

12/04/2025

EPCORE FL-1: Epcoritamab Plus Lenalidomide and Rituximab for Follicular Lymphoma

Gilles Salles, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Gurbakhash Kaur, MD

View All

Three medical professionals, including Dr. Gurbakhash Kaur, Dr. Rohit Gosain, and Dr. Rahul Gosain, discussing treatment algorithms for newly diagnosed and smoldering multiple myeloma in 2026.

Gurbakhash Kaur, MD

07/29/2026

2026 Treatment Algorithms for Newly Diagnosed and Smoldering Multiple Myeloma

Gurbakhash Kaur, MDRahul Gosain, MD, MBARohit Gosain, MD

Hagop Kantarjian, MD

View All

Hagop Kantarjian, MD

09/22/2026

Ponatinib in CML After Second-Generation TKI Treatment

Hagop Kantarjian, MDFadi Haddad, MD

Hagop Kantarjian, MD

09/15/2026

Breaking Down the 5-Year Data on Ponatinib in CML

Fadi Haddad, MDHagop Kantarjian, MD

Hamza Hashmi, MD

View All

Hamza Hashmi, MD

10/01/2026

Ep. 2: Newly Released Data Support Long-Term Efficacy of CAR-T Therapy in Multiple Myeloma

Rahul Banerjee, MD, FACPHamza Hashmi, MD

Hamza Hashmi, MD

09/30/2026

Ep. 1: Moving Closer to a Cure in Multiple Myeloma Treatment

Rahul Banerjee, MD, FACPHamza Hashmi, MD

$Two doctors, Dr. Maximilian Merz and Dr. Hamza Hashmi, discuss sequencing BCMA-directed therapies for relapsed/refractory multiple myeloma at a medical conference.$

Hamza Hashmi, MD

08/18/2026

CAR-T First Emerges as Recommended Therapy For Relapsed/Refractory Multiple Myeloma

Hamza Hashmi, MDMaximilian Merz, MD

$Two doctors, Dr. Hamza Hashmi and Dr. Maximilian Merz, discussing optimizing Cilta-Cel use in relapsed/refractory multiple myeloma.$

Hamza Hashmi, MD

08/18/2026

Earlier Line Therapy With Cilta-Cel To Treat Relapsed/Refractory Multiple Myeloma

Hamza Hashmi, MDMaximilian Merz, MD

Hamza Hashmi, MD

06/20/2026

Talquetamab Side Effects: Management and Counseling Strategies

Sawyer Bawek, DOHamza Hashmi, MD

Hamza Hashmi, MD

06/17/2026

MajesTEC-9 Data and Teclistamab in Earlier Treatment Lines for Multiple Myeloma

Sawyer Bawek, DOHamza Hashmi, MD

Hamza Hashmi, MD

06/16/2026

The Growing Role of CAR T-Cell Therapies in Multiple Myeloma

Sawyer Bawek, DOHamza Hashmi, MD

Experts discussing targeted therapy strategies for managing toxicities in multiple myeloma treatment, featuring Dr. Hamza Hashmi, Dr. Cesar Rodriguez, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Hamza Hashmi, MD

05/20/2026

Bispecific Therapy in Multiple Myeloma: Strategies for Managing Toxicities

Hamza Hashmi, MDCesar Rodriguez, MDRahul Gosain, MD, MBARohit Gosain, MD

Hamza Hashmi, MD

01/16/2026

Collaboration is Key to Safely Transition Care in MM Following Cellular Therapy

Hamza Hashmi, MDShreyas Kalantri, MD

Hamza Hashmi, MD

01/03/2026

Bispecific Antibodies and CAR T Redefine Early-Line Treatment in Multiple Myeloma

Robert Orlowski, MD, PhDHamza Hashmi, MD

Hamza Hashmi, MD

12/26/2025

Year in Review: The Rise of Cellular Immunotherapy for Multiple Myeloma

Hamza Hashmi, MD

Harold Burstein, MD, PhD

View All

Harold Burstein, MD, PhD

02/10/2026

4 Significant Trials for HER2+ Breast Cancer at SABCS 2025

Harold Burstein, MD, PhDRohit Gosain, MDRahul Gosain, MD, MBA

Heather Kline, MS, APRN, FNP-C

View All

Group photo of four medical professionals, including Dr. Timothy Brown, Dr. Heather Kline, Dr. Rohit Gosain, and Dr. Rahul Gosain, discussing pancreatic cancer management.

Heather Kline, MS, APRN, FNP-C

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Helena Yu, MD

View All

Helena Yu, MD

06/16/2025

Ep. 3: How to Choose the Best First-Line Therapy for Patients With EGFR-Mutated NSCLC

Susan Scott, MDEstelamari Rodriguez, MD, MPHHelena Yu, MD

Helena Yu, MD

06/16/2025

Ep. 2: New Insights From the MARIPOSA Trial: Amivantamab Plus Lazertinib for EGFR-Mutated NSCLC

Helena Yu, MDJoshua Sabari, MD

Helena Yu, MD

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Hetty Carraway, MD

08/04/2026

Ep. 3: Managing Imetelstat Toxicities in Lower-Risk MDS

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Hetty Carraway, MD

08/01/2026

Ep. 2: Imetelstat, Luspatercept, and ESAs: Treatment Sequencing in Lower-Risk MDS

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Hetty Carraway, MD

07/29/2026

Ep. 1: The Growing Role of Next-Generation Sequencing and IPSS-M in Lower-Risk MDS

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Hetty Carraway, MD

Jacob Sands, MD

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Jasmin Hundal, MD

View All

Jasmin Hundal, MD

07/23/2026

Trastuzumab Deruxtecan and the Evolution of HER2-Directed Therapy

Jasmin Hundal, MD

06/11/2026

Jasmin Hundal, MD

High magnification image of cancerous tissue stained with H&E, showing tumor cells and surrounding stroma, relevant for oncology research and cancer diagnosis.

Jasmin Hundal, MD

12/02/2025

Comparative Safety of CDK4/6 Inhibitors: Key AEs and Management Approaches

Jasmin Hundal, MD

06/11/2025

Strategic Timing for Multidisciplinary Care in Breast Cancer

Jasmin Hundal, MDMatthew Kurian, MD

Jason Westin, MD, MS, FASCO

View All

Jason Westin, MD, MS, FASCO

05/16/2025

CAR-T Toxicity Check: From Approval to Practice, Managing Side Effects of CAR-T Therapy

Jason Westin, MD, MS, FASCOSurbhi Sidana, MD

Jayastu Senapati, MBBS

View All

Jayastu Senapati, MBBS

01/16/2026

Azacitidine in AML: Key Takeaways From the PARADIGM Study

Jayastu Senapati, MBBSUma Borate, MBBS

Jayastu Senapati, MBBS

12/23/2025

Improving Venetoclax and Other Targeted Therapies in AML

Zachary Braunstein, MDJayastu Senapati, MBBS

Jeffrey Zhong, MD

View All

Jeffrey Zhong, MD

03/11/2026

PARP Inhibitor Combination Therapy in Metastatic Prostate Cancer

Karan Jatwani, MDJeffrey Zhong, MD

Jennifer Vaughn, MD

View All

An informative medical panel discussion on venous thromboembolism (VTE) featuring Dr. Jennifer Vaughn, Dr. Nicolas Gallastegui Crestani, Dr. Rahul Gosain, and Dr. Rohit Gosain, focusing on challenging.

Jennifer Vaughn, MD

11/08/2025

Clinical Decision-Making in Unprovoked vs Provoked Pulmonary Embolism

Jennifer Vaughn, MDNicolas Gallastegui Crestani, MDRahul Gosain, MD, MBARohit Gosain, MD

Jenny Truong, RN

View All

Jenny Truong, RN

09/03/2026

The Critical Role of Supportive Care in Managing Multiple Myeloma

Ajai Chari, MDSamantha Shenoy, NPJenny Truong, RNRahul Gosain, MD, MBARohit Gosain, MD

Jimmitti Teysir, MD

View All

Jimmitti Teysir, MD

06/12/2026

How Molecular Profiling Guides Targeted Therapy Options in HR–Positive Breast Cancer

Jimmitti Teysir, MDYa Haddy Sallah, MD, MPH

Jing Wang, MD

View All

Jing Wang, MD

01/08/2026

Early Intervention Strategies in High-Risk Smoldering Multiple Myeloma

Anuja V. Abhyankar, MDJing Wang, MD

John Leonard, MD

View All

DLBCL treatment algorithm 2025, oncological updates, lymphoma therapy, Dr. John Leonard, Dr. Rohit Gosain, Dr. Rahul Gosain, cancer treatment advancements, hematologic oncology, oncological research, latest lymphoma treatment strategies.

John Leonard, MD

07/22/2025

The DLBCL Treatment Algorithm in 2025

John Leonard, MD

John Mascarenhas, MD

View All

Dr. John Mascarenhas, Dr. Rahul Gosain, and Dr. Rohit Gosain discuss new treatment options for essential thrombocythemia.

John Mascarenhas, MD

Abhishek Maiti, MDJorge Cortes, MD

Jorge Cortes, MD

10/14/2025

Treating CML in 2025: TKIs and Transplant

Jorge Cortes, MDRahul Gosain, MD, MBARohit Gosain, MD

Joseph Mikhael, MD, MEd

View All

Myeloma specialist Dr. Joseph Mikhael answers community questions on CAR T-Cell Therapy, MRD, and CELMoDs, featuring Dr. Rohit Gosain and Dr. Rahul Gosain at OncUpdates.

Joseph Mikhael, MD, MEd

Joshua Brody, MD

12/17/2025

Primary Results From EPCORE FL-1 Presented at ASH 2025

Urshila Durani, MD, MPHJoshua Brody, MD

Joshua Meeks, MD, PhD

View All

Visual overview of the updated bladder cancer treatment algorithm featuring medical professionals Dr. Joshua Meeks, Dr. Stephanie Berg, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Joshua Meeks, MD, PhD

04/06/2026

The Updated Treatment Algorithm for Bladder Cancer

Stephanie Berg, DOJoshua Meeks, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Joshua Meeks, MD, PhD

11/26/2025

Discussing Challenging Cases in NMIBC

Joshua Meeks, MD, PhDShilpa Gupta, MDRohit Gosain, MDRahul Gosain, MD, MBA

Joshua Meeks, MD, PhD

06/16/2025

Ep. 5: NIAGARA Trial: Perioperative Durvalumab Enhances DFS in MIBC

Joshua Meeks, MD, PhD

06/16/2025

Ep. 2: Clinical Implications of Circulating Tumor DNA in MIBC

Petros Grivas, MD, PhDJoshua Meeks, MD, PhD

Joshua Meeks, MD, PhD

06/14/2025

NIAGARA Trial: Perioperative Durvalumab for MIBC (Full Video)

Joshua Meeks, MD, PhDKarine Tawagi, MDNeal Shore, MD, FACSPetros Grivas, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Joshua Richter, MD

View All

Joshua Richter, MD

08/04/2026

CAR T-Cell Therapy in Multiple Myeloma: Managing Adverse Effects Through Collaboration

Caitlin Costello, MDJoshua Richter, MDRahul Gosain, MD, MBARohit Gosain, MD

Joshua Sabari, MD

View All

Expert discussion on managing side effects of EGFR inhibitors in non-small cell lung cancer (NSCLC) with Dr. Azam Farooqi, Dr. Joshua Sabari, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

Joshua Sabari, MD

12/16/2025

Clinical Insights: Metastatic EGFR+ NSCLC from MARIPOSA and PALOMA-3

Joshua Sabari, MDAlexander Spira, MD, PhD, FACP, FASCODanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MD

FDA approval of Zongertinib in HER2-mutated NSCLC for targeted cancer treatment.

Joshua Sabari, MD

08/25/2025

FDA Approval of Zongertinib in HER2-Mutated NSCLC

Joshua Sabari, MDRahul Gosain, MD, MBARohit Gosain, MD

Joshua Sabari, MD

06/16/2025

Ep. 2: New Insights From the MARIPOSA Trial: Amivantamab Plus Lazertinib for EGFR-Mutated NSCLC

Helena Yu, MDJoshua Sabari, MD

Joshua Sabari, MD

06/16/2025

EP. 1: Targeted Therapies in EGFR-Mutated NSCLC: Managing Treatment-Related AEs

Estelamari Rodriguez, MD, MPHHelena Yu, MDJoshua Sabari, MD

Joshua Sabari, MD

06/15/2025

MARIPOSA: Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC

Estelamari Rodriguez, MD, MPHHelena Yu, MDJoshua Sabari, MDSusan Scott, MDRahul Gosain, MD, MBARohit Gosain, MD

Judy Fitzgerald

View All

Judy Fitzgerald

01/04/2026

Patient Advocacy Brings Breast Cancer Vaccine to Phase 1 Trial

Judy FitzgeraldKarissa Britten, MD

Julia Rotow, MD

View All

Julia Rotow, MD

03/19/2026

Ep. 3: Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC

Eric Singhi, MDSarah Goldberg, MD, MPHFawzi Abu Rous, MDJulia Rotow, MDSusan Scott, MD

Julia Rotow, MD

03/17/2026

Ep. 2: Clinical Insights: Proactive Toxicity Management and CNS Control in EGFR-Mutant NSCLC

Eric Singhi, MDSarah Goldberg, MD, MPHSusan Scott, MDFawzi Abu Rous, MDJulia Rotow, MD

Julia Rotow, MD

03/14/2026

Ep. 1: OS Benefit and Patient-Centered Delivery Advances in EGFR-Mutant NSCLC

Eric Singhi, MDSusan Scott, MDSarah Goldberg, MD, MPHFawzi Abu Rous, MDJulia Rotow, MD

Julie Vose, MD, MBA

View All

Julie Vose, MD, MBA

02/26/2026

Bispecifics, BTK Inhibitors, and Immunotherapy Drive Lymphoma Advances

Julie Vose, MD, MBARahul Gosain, MD, MBARohit Gosain, MD

Karan Jatwani, MD

View All

Karan Jatwani, MD

05/27/2026

Refining the Post-IO Strategy in mRCC: The Role of TKIs and the Nuance of Timing

Karan Jatwani, MDUrvi Patel, DO, MPH

Karan Jatwani, MD

03/11/2026

PARP Inhibitor Combination Therapy in Metastatic Prostate Cancer

Karan Jatwani, MDJeffrey Zhong, MD

Karan Jatwani, MD

03/06/2026

Capivasertib Plus Abiraterone in Metastatic Prostate Cancer

Alan Bryce, MDKaran Jatwani, MD

Karan Jatwani, MD

06/10/2025

Second-Line Treatment Sequencing in Metastatic RCC

Enrique Grande, MD, PhD, MSCKaran Jatwani, MD

Karen Merritt

View All

Karen Merritt

02/03/2026

FDA Update Reflects Need for Genetic Testing Prior to Capecitabine

Karen MerrittVimal Scott Kapoor, MD, BSc, MSc

Karine Tawagi, MD

View All

Karine Tawagi, MD

03/14/2026

PEACE-3 OS Data Support Radium-223 Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Sindhuja Kadambi, MD, MSKarine Tawagi, MD

Karine Tawagi, MD

06/16/2025

Ep. 4: The Oncologist’s Role in Counseling Patients With MIBC Through Complex Treatment Decisions

Karine Tawagi, MD

06/16/2025

Ep. 1: Current Treatment Strategies for Muscle-Invasive Bladder Cancer

Karine Tawagi, MD

06/14/2025

NIAGARA Trial: Perioperative Durvalumab for MIBC (Full Video)

Joshua Meeks, MD, PhDKarine Tawagi, MDNeal Shore, MD, FACSPetros Grivas, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Karissa Britten, MD

View All

Karissa Britten, MD

01/04/2026

Patient Advocacy Brings Breast Cancer Vaccine to Phase 1 Trial

Judy FitzgeraldKarissa Britten, MD

Karissa Britten, MD

12/19/2025

Evolving Treatment Paradigms in Advanced Breast Cancer: Key Trial Updates From SABCS 2025

Karissa Britten, MDVaishali Deenadayalan, MD

Karissa Britten, MD

12/19/2025

Key Insights From the NATALEE Trial

Karissa Britten, MDMatthew Kurian, MD

Karthik Giridhar, MD

View All

Karthik Giridhar, MD

11/10/2025

ESMO 2025: Updates in the HR+ Metastatic Breast Cancer Landscape

Sarah Premji, MDKarthik Giridhar, MD

Katy Beckermann, MD, PhD

View All

A woman doctor smiling, with text about reviewing RCC treatment algorithms and trial regimens, on a green background.

Katy Beckermann, MD, PhD

03/31/2026

Reviewing the RCC Treatment Algorithm and Novel Trial Regimens

Katy Beckermann, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Kevin Kalinsky, MD, MS, FASCO

View All

Kevin Kalinsky, MD, MS, FASCO

10/03/2026

Utilizing Inavolisib for Endocrine-Resistant, PIK3CA–mutated, HR+, HER2-, Metastatic Breast Cancer

William Gradishar, MDVirginia Kaklamani, MD, DScKevin Kalinsky, MD, MS, FASCOAlia Nazarullah, MDRahul Gosain, MD, MBARohit Gosain, MD

Advanced cancer specialists discussing innovative treatment options for HR+ metastatic breast cancer at OncUpdates conference.

Kevin Kalinsky, MD, MS, FASCO

03/02/2026

Standard of Care Treatments for HR+ Metastatic Breast Cancer

Kevin Kalinsky, MD, MS, FASCORahul Gosain, MD, MBARohit Gosain, MD

Kevin Kalinsky, MD, MS, FASCO

12/18/2025

SABCS 2025: Evolving Role of CDK4/6 Inhibitors and SERDs in ER-Positive Breast Cancer

Kevin Kalinsky, MD, MS, FASCOSarah Premji, MD

Kevin Zablonski, MD

View All

Kevin Zablonski, MD

07/30/2026

ISTH 2026: Key Takeaways in Cancer-Associated Thrombosis and Thrombocytopenia

William Archibald, MDKevin Zablonski, MD

Kingsley Nnawuba, MD

View All

Kingsley Nnawuba, MD

01/13/2026

Oncologists Review Practice-Changing Lymphoma Findings From ASH 2025

Kingsley Nnawuba, MDUrshila Durani, MD, MPH

Komal Jhaveri, MD, FACP

View All

Komal Jhaveri, MD, FACP

06/07/2026

Biomarker Testing and Targeted Therapy Advancements in Metastatic Breast Cancer

Komal Jhaveri, MD, FACPSarah Premji, MD

Advanced cancer research team discussing clinical implications of HER2 testing and targeted therapies at OncUpdates.

Komal Jhaveri, MD, FACPMatthew Kurian, MD

Krina Patel, MD, MSc

View All

Panel discussion on treatment options in multiple myeloma featuring Dr. Marco Davila, Dr. Krina Patel, Dr. Rohit Gosain, and Dr. Rahul Gosain at OncUpdates.

Krina Patel, MD, MSc

07/27/2026

Myeloma Specialists Discuss Treatment Options in Multiple Myeloma Cases

Marco Davila, MD, PhDKrina Patel, MD, MScRahul Gosain, MD, MBARohit Gosain, MD

Kriti Ahuja, MD

View All

Kriti Ahuja, MD

01/24/2026

ASCO GI 2026 Highlights: PARP Inhibitors Plus Immunotherapy

Kriti Ahuja, MDDina Ioffe, MD

Kriti Ahuja, MD

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Laura Huppert, MD

12/31/2025

CDK4/6 Inhibitor Selection in HR+ Metastatic Breast Cancer (Full Video)

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Lauren Laderman, MD

View All

Lauren Laderman, MD

02/05/2026

The Uncertain Role of ctDNA in Colorectal Cancers

Lauren Laderman, MDUdhayvir Singh Grewal, MD

Lauren M. Granat, DO, MS

View All

Lauren M. Granat, DO, MS

12/22/2025

ASH 2025 Signals Shift Toward Personalized, Time-Limited Therapy in Chronic Lymphocytic Leukemia

Lauren M. Granat, DO, MS

Legal

View All

Lisa Liu, MD

View All

Lisa Liu, MD

06/10/2025

Latest GI Cancer Trends From ASCO 2025: Molecular Testing, IO Strategies & Targeted Therapy

Seyi Abidoye, MBBSLisa Liu, MD

Loretta Nastoupil, MD

View All

Professional healthcare presentation on expanding community access to bispecific therapies with Dr. Loretta Nastoupil and Dr. Raji Shameem.

Loretta Nastoupil, MD

09/10/2026

Part 2: How to Expand Community Access to Bispecific Therapies

Loretta Nastoupil, MDRaji Shameem, MD

Healthcare professionals discussing safe administration of bispecific antibodies in community oncology setting.

Loretta Nastoupil, MD

09/02/2026

Part 1: Safe Administration of Bispecific Antibodies in the Community Oncology Setting

Loretta Nastoupil, MDRaji Shameem, MD

Luciano Costa, MD

View All

Dr. Luciano Costa, Dr. Rahul Gosain, and Dr. Rohit Gosain discussing approved treatments for relapsed multiple myeloma, highlighting recent advances in oncology research.

Luciano Costa, MD

03/10/2026

Teclistamab Plus Daratumumab Approved for Relapsed or Refractory Multiple Myeloma After MajesTEC-3

Luciano Costa, MDRahul Gosain, MD, MBARohit Gosain, MD

Luis Raez, MD, FACP, FCCP, FASCO

View All

Luis Raez, MD, FACP, FCCP, FASCO

03/15/2026

Ep. 3: Intensification Strategies and CNS Management in EGFR-Mutant NSCLC

Chinmay Jani, MDLuis Raez, MD, FACP, FCCP, FASCO

Luis Raez, MD, FACP, FCCP, FASCO

03/13/2026

Ep. 2: Subcutaneous Amivantamab Reshapes Frontline EGFR-Mutant NSCLC Care

Chinmay Jani, MDLuis Raez, MD, FACP, FCCP, FASCO

Luis Raez, MD, FACP, FCCP, FASCO

03/11/2026

Ep. 1: Overcoming Infusion Barriers in EGFR-Mutant Non–Small Cell Lung Cancer

Chinmay Jani, MDLuis Raez, MD, FACP, FCCP, FASCO

Madison Canning, MD

View All

Madison Canning, MD

12/31/2025

Emerging Roles of Biomarkers in HER2-Positive Breast Cancer

Yash Agrawal, MDMadison Canning, MD

Mahesh Swaminathan, MB, MS

View All

Mahesh Swaminathan, MB, MS

12/20/2025

Ibrutinib Updates in CLL From ASH 2025

Mahesh Swaminathan, MB, MSVanthana Bharthi, MD

Mahesh Swaminathan, MB, MS

12/18/2025

Breaking Down ASH 2025 Data on Frontline Pirtobrutinib in CLL

Bita Fakhri, MD, MPHMahesh Swaminathan, MB, MS

Main Menu

View All

Manas Pustake, MD

View All

Manas Pustake, MD

06/19/2026

Practice-Changing Shifts in GU Cancers From ASCO 2026

Manas Pustake, MD

Rahul Gosain, MD, MBARohit Gosain, MDGeoffrey Ku, MDRutika Mehta, MD, MB, MPHManish Shah, MDNataliya Uboha, MD, PhD

Marco Davila, MD, PhD

View All

Marco Davila, MD, PhD

07/27/2026

Myeloma Specialists Discuss Treatment Options in Multiple Myeloma Cases

Marco Davila, MD, PhDKrina Patel, MD, MScRahul Gosain, MD, MBARohit Gosain, MD

Maria A. Velez, MD, MS

View All

Maria A. Velez, MD, MS

06/10/2025

Shifting Paradigms in Lung Cancer Care: Insights From ASCO 2025

Maria A. Velez, MD, MS

Mariam Haji Ahmad, MBBCh

View All

Mariam Haji Ahmad, MBBCh

01/17/2026

Impact of ADCs in Early TNBC Treatment

Mariam Haji Ahmad, MBBChAlexis Levee, MD

Marina Beltrami-Moreira, MD

View All

1. Expert panel discussing diagnosis and treatment of anemia and iron overload in cancer patients at OncUpdates conference.

Marina Beltrami-Moreira, MD

12/07/2025

Challenging Cases: Diagnosis and Treatment of Anemia or Iron Overload

Marina Beltrami-Moreira, MDRahul Gosain, MD, MBARohit Gosain, MD

Mark Awad, MD, PhD

View All

Metastatic NSCLC treatment insights with Dr. Mark Awad, focusing on targeted therapies without mutations, featuring expert oncology discussions from OncUpdates.

Mark Awad, MD, PhD

Rahul Gosain, MD, MBARohit Gosain, MDShilpa Gupta, MDChad Reichard, MDSia Daneshmand, MDMatt Galsky, MD

Matthew Goetz, MD

View All

Matthew Goetz, MD

Karissa Britten, MDMatthew Kurian, MD

Matthew Kurian, MD

10/28/2025

ESMO 2025 Breaking New Ground in Breast Cancer: Five Trials to Know

Matthew Kurian, MD

06/11/2025

Strategic Timing for Multidisciplinary Care in Breast Cancer

Jasmin Hundal, MDMatthew Kurian, MD

Matthew Kurian, MD

06/10/2025

Key Takeaways From ASCO 2025 for Hormone-Receptor+ Metastatic Breast Cancer

Komal Jhaveri, MD, FACPMatthew Kurian, MD

Matthew Lunning, DO, FACP

View All

Hamza Hashmi, MDMaximilian Merz, MD

Three medical professionals discussing treatment options for late relapsed multiple myeloma, featuring Dr. Maximilian Merz, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Maximilian Merz, MD

08/06/2026

Treatment Options and Sequencing for Late Relapsed/Refractory Multiple Myeloma

Maximilian Merz, MDRahul Gosain, MD, MBARohit Gosain, MD

Mazyar Shadman, MD, MPH

View All

Evolving treatment algorithms for newly diagnosed and relapsed DLBCL featuring three doctors from OncUpdates.

Mazyar Shadman, MD, MPH

09/24/2026

Evolving Treatment Algorithms for Newly Diagnosed and Relapsed DLBCL

Mazyar Shadman, MD, MPHRahul Gosain, MD, MBARohit Gosain, MD

OncUpdates theme focusing on colorectal cancer treatment and oncology advancements, featuring oncologists Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Mazyar Shadman for community oncology education.

Mazyar Shadman, MD, MPH

09/11/2025

CLL Treatment Landscape for the Community Oncologist

Mazyar Shadman, MD, MPHRahul Gosain, MD, MBARohit Gosain, MD

Meghana Singh, MD

View All

Meghana Singh, MD

Midhun Malla, MDMichael A. Morse, MD, FACP, MHSBenjamin Leon Musher, MDRahul Gosain, MD, MBARohit Gosain, MD

Michael A. Morse, MD, FACP, MHS

06/12/2026

Dose Optimization and Pharmacogenomic Testing in Pancreatic Cancer Treatment

Midhun Malla, MDMichael A. Morse, MD, FACP, MHSBenjamin Leon Musher, MDRahul Gosain, MD, MBARohit Gosain, MD

Michael A. Morse, MD, FACP, MHS

06/06/2026

Choosing Frontline Therapy for Patients With Metastatic Pancreatic Adenocarcinoma

Midhun Malla, MDMichael A. Morse, MD, FACP, MHSBenjamin Leon Musher, MDRahul Gosain, MD, MBARohit Gosain, MD

Michael A. Morse, MD, FACP, MHS

06/05/2026

Frontline Treatment Selection in Metastatic Pancreatic Cancer

Midhun Malla, MDMichael A. Morse, MD, FACP, MHSBenjamin Leon Musher, MDRahul Gosain, MD, MBARohit Gosain, MD

Michael A. Morse, MD, FACP, MHS

05/31/2026

Clinical Insights: Evolving Paradigms in Metastatic Pancreatic Cancer

Midhun Malla, MDMichael A. Morse, MD, FACP, MHSBenjamin Leon Musher, MDRahul Gosain, MD, MBARohit Gosain, MD

Michael Serzan, MD

View All

Michael Serzan, MD

06/22/2026

Adjuvant Immunotherapy in RCC: Insights From RAMPART

Sumanta Pal, MD, FASCOMichael Serzan, MD

$Medical professional holding a stethoscope, focusing on the evolving landscape of refractory renal cell carcinoma in cancer treatment.$

Michael Serzan, MD

05/14/2026

Michael Serzan, MD

06/11/2025

New Questions in Muscle-Invasive Bladder Cancer After the NIAGARA Trial

Albert Jang, MDMichael Serzan, MD

Michael Serzan, MD

06/11/2025

Highlights From the AMPLITUDE Study at ASCO 2025

Albert Jang, MDMichael Serzan, MD

Michael Serzan, MD

06/11/2025

Updated CheckMate 214 Results Support Ipi-Nivo for Favorable-Risk Kidney Cancer

Albert Jang, MDMichael Serzan, MD

Michael Serzan, MD

06/10/2025

NIAGARA Trial: A New Standard of Care in MIBC

Petros Grivas, MD, PhDMichael Serzan, MD

Michael Serzan, MD

Midhun Malla, MDMichael A. Morse, MD, FACP, MHSBenjamin Leon Musher, MDRahul Gosain, MD, MBARohit Gosain, MD

Managing side effects of pancreatic cancer treatment with expert insights from oncologists and latest research updates on ToxCheck.

Midhun Malla, MD

05/28/2025

Managing Toxicities of FOLFIRINOX and Nab-Paclitaxel Plus Gemcitabine

Midhun Malla, MDRachna Shroff, MD, MS, FASCO

Miles Hsu, MD

View All

Miles Hsu, MD

06/14/2026

Integrating ctDNA Into Muscle-Invasive Bladder Cancer Treatment

Miles Hsu, MD

03/15/2026

Novel HER2–Targeting Therapies in Urothelial Cancer

Miles Hsu, MDBrendan Guercio, MD

Mitchell Alexander Parma, MD

View All

Mitchell Alexander Parma, MD

06/11/2025

ASCO 2025: Key Clinical Trials in Resectable NSCLC

Eric Singhi, MDMitchell Alexander Parma, MD

Mycal Casey, DO

View All

Mycal Casey, DO

12/24/2025

Reviewing ASH 2025 Data for ALL and TP53-Mutated AML or MDS

Abhishek Maiti, MDMycal Casey, DO

Narjust Florez, MD, FASCO

View All

Narjust Florez, MD, FASCO

06/22/2026

HARMONi-6 and LIBRETTO-432: Major Trial Updates for NSCLC Subtypes

Arthi Sridhar, MDNarjust Florez, MD, FASCO

Narjust Florez, MD, FASCO

07/25/2025

Innovación dirigida: datopotamab deruxtecan en el tratamiento del cáncer de pulmón no microcítico avanzado

Coral Olazagasti, MDNarjust Florez, MD, FASCO

Narjust Florez, MD, FASCO

07/02/2025

Datopotamab Deruxtecan in NSCLC: A Closer Look at TROP2-Targeted Therapy

Coral Olazagasti, MDNarjust Florez, MD, FASCO

Natalie Reizine, MD

View All

Natalie Reizine, MD

03/16/2026

A Personalized Approach to Treating GU Cancers

Sophia Kamran, MDNatalie Reizine, MD

Nataliya Uboha, MD, PhD

View All

OncUpdates article on Zanidatamab combinations approved for HER2+ gastroesophageal cancers featuring Dr. Natalya Uboha, Dr. Rahul Gosain, and Dr. Rohit Gosain.

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

Advanced medical professionals discussing evolving treatment options for therapy-related and de novo AML in hematology research.

Naval Daver, MD

02/11/2026

Challenging Cases: The Evolving Treatment Landscape for Therapy-Related and De Novo AML

Naval Daver, MDRahul Gosain, MD, MBARohit Gosain, MD

$Overcoming challenges in relapsed or refractory FLT3-positive AML featuring Dr. Uma Borate, Dr. Navali Daver, Dr. Rohit Gosain, and Dr. Rahul Gosain, discussing innovative approaches in hematology and oncology.$

POTOMAC Trial Breakthrough: Durvalumab Plus BCG Shows Improved Recurrence-Free Survival

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Neal Shore, MD, FACS

06/09/2026

POTOMAC Trial Breakthrough: Durvalumab Plus BCG Shows Improved Disease-Free Survival

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Neal Shore, MD, FACS

06/08/2026

Defining High-Risk Non–Muscle-Invasive Bladder Cancer and the Limits of BCG Alone

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Neal Shore, MD, FACS

06/04/2026

Clinical Insights: Integrating Durvalumab Into Non–Muscle-Invasive Bladder Cancer Care

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Neal Shore, MD, FACS

06/16/2025

Ep. 3: Key Takeaways From the NIAGARA Trial for Patients With MIBC

Neal Shore, MD, FACS

06/14/2025

NIAGARA Trial: Perioperative Durvalumab for MIBC (Full Video)

Joshua Meeks, MD, PhDKarine Tawagi, MDNeal Shore, MD, FACSPetros Grivas, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Neena Vijayvergia, MD

View All

Neena Vijayvergia, MD

07/02/2026

ASCO 2026: Key GI Trials Shaping Clinical Practice

Neena Vijayvergia, MDRahul Gosain, MD, MBARohit Gosain, MD

Neena Vijayvergia, MD

01/27/2026

64Cu-SARTATE Improves Tumor Detection in GEP-NETs

Udhayvir Singh Grewal, MDNeena Vijayvergia, MD

Neena Vijayvergia, MD

06/10/2025

Interpreting the Broad Cabozantinib Label for NETs

Neena Vijayvergia, MDShruti Patel, MD

Neena Vijayvergia, MD

06/10/2025

Considering Frontline PRRT in NETs

Neena Vijayvergia, MDShruti Patel, MD

Neil Iyengar, MD

View All

Neil Iyengar, MD

01/06/2026

PI3K/AKT Inhibitor Side Effect Management in Metastatic Breast Cancer

Emily Gallagher, MD, PhDNeil Iyengar, MDRohit Gosain, MDRahul Gosain, MD, MBA

Nerea Lopetegui-Lia, MD

View All

Nerea Lopetegui-Lia, MD

06/04/2026

Six Practice-Informing Breast Cancer Trials From ASCO 2026

Nerea Lopetegui-Lia, MD

12/28/2025

De-escalation and Sequencing Strategies Shape HER2-Positive Breast Cancer Care at SABCS 2025

Nerea Lopetegui-Lia, MDYa Haddy Sallah, MD, MPH

Nerea Lopetegui-Lia, MD

12/26/2025

SABCS 2025: HER2CLIMB-05 and DESTINY Trials Point to More Individualized Care in HER2-Positive Breast Cancer

Nerea Lopetegui-Lia, MDSusan Dent, BSc, MD

Breast cancer awareness, woman holding her chest, health precautions, self-exam for early detection, medical health, oncology, cancer prevention, healthcare tips.

Nerea Lopetegui-Lia, MD

12/01/2025

The Evolving Role of Ribociclib and Optimizing First-Line Treatment in HR+/HER2- Metastatic Breast Cancer

Nerea Lopetegui-Lia, MD

Nicholas Hornstein, MD, PhD

View All

Nicholas Hornstein, MD, PhD

01/22/2026

Expert Perspectives on the BREAKWATER Trial in Metastatic Colorectal Cancer

Daniel Tuerff, MDNicholas Hornstein, MD, PhD

Nicholas Hornstein, MD, PhD

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

Nicholas Simon, MD

View All

Nicholas Simon, MD

03/12/2026

Cabozantinib and Novel Doublets in Advanced RCC

Nicholas Simon, MDSumanta Pal, MD, FASCO

Nicholas Simon, MD

03/12/2026

First-Line Treatment Strategies in Metastatic Renal Cell Carcinoma

Andre Kydd, MD, PhDNicholas Simon, MD

Nico Gagelmann, MD

View All

Three medical professionals, Dr. Nico Gagelmann, Dr. Rohit Gosain, and Dr. Rahul Gosain, discussing JAK inhibitors and treatment algorithms for myelofibrosis.

Ep. 3: Incorporating the SENTRY Regimen and Managing Side Effects in Myelofibrosis

Nikolai Podoltsev, MD, PhDRaajit Rampal, MD, PhDSrinivas Tantravahi, MBBS, MRCPPankit Vachhani, MDRahul Gosain, MD, MBARohit Gosain, MD

Nikolai Podoltsev, MD, PhD

08/26/2026

Ep. 2: Phase 3 SENTRY Trial: Selinexor Plus Ruxolitinib in Myelofibrosis

Nikolai Podoltsev, MD, PhDRaajit Rampal, MD, PhDSrinivas Tantravahi, MBBS, MRCPPankit Vachhani, MDRahul Gosain, MD, MBARohit Gosain, MD

Nikolai Podoltsev, MD, PhD

08/19/2026

Ep. 1: The JAK Inhibitor Paradigm and Unmet Needs in Myelofibrosis

Nikolai Podoltsev, MD, PhDRaajit Rampal, MD, PhDSrinivas Tantravahi, MBBS, MRCPPankit Vachhani, MDRahul Gosain, MD, MBARohit Gosain, MD

Nikolai Podoltsev, MD, PhD

08/11/2026

Selinexor Combination Therapy in Myelofibrosis: SENTRY Trial Insights

Nikolai Podoltsev, MD, PhDRaajit Rampal, MD, PhDSrinivas Tantravahi, MBBS, MRCPPankit Vachhani, MDRahul Gosain, MD, MBARohit Gosain, MD

Nina Sanford, MD

View All

Group of three medical professionals discussing guidelines for systemic therapy during radiation therapy.

Nina Sanford, MD

Omid Hamid, MD

Daraxonrasib Approved for Previously Treated Metastatic Pancreatic Cancer

OncUpdates

08/25/2026

FDA Approves Zanidatamab-hrii Plus Tislelizumab-jsgr for HER2-Positive Gastroesophageal Adenocarcinoma

OncUpdates

08/13/2026

FDA Grants Accelerated Approval to Iberdomide Combination for Relapsed Multiple Myeloma

OncUpdates

05/05/2026

OncUpdates

03/17/2026

09/23/2025

Advancements in Oncology: Orlando

OncUpdates

09/08/2025

Advancements in Oncology: San Antonio

OncUpdates

Onyee Chan, MD

View All

Onyee Chan, MD

Petros Grivas, MD, PhD

06/16/2025

Ep. 2: Clinical Implications of Circulating Tumor DNA in MIBC

Petros Grivas, MD, PhDJoshua Meeks, MD, PhD

Petros Grivas, MD, PhD

06/14/2025

NIAGARA Trial: Perioperative Durvalumab for MIBC (Full Video)

Joshua Meeks, MD, PhDKarine Tawagi, MDNeal Shore, MD, FACSPetros Grivas, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Petros Grivas, MD, PhD

View All

Raajit Rampal, MD, PhD

09/09/2026

Ep. 4: Ongoing Trials and Future Treatment Paradigms for Myelofibrosis

Nikolai Podoltsev, MD, PhDRaajit Rampal, MD, PhDSrinivas Tantravahi, MBBS, MRCPPankit Vachhani, MDRahul Gosain, MD, MBARohit Gosain, MD

Raajit Rampal, MD, PhD

09/02/2026

Ep. 3: Incorporating the SENTRY Regimen and Managing Side Effects in Myelofibrosis

Nikolai Podoltsev, MD, PhDRaajit Rampal, MD, PhDSrinivas Tantravahi, MBBS, MRCPPankit Vachhani, MDRahul Gosain, MD, MBARohit Gosain, MD

Raajit Rampal, MD, PhD

08/26/2026

Ep. 2: Phase 3 SENTRY Trial: Selinexor Plus Ruxolitinib in Myelofibrosis

Nikolai Podoltsev, MD, PhDRaajit Rampal, MD, PhDSrinivas Tantravahi, MBBS, MRCPPankit Vachhani, MDRahul Gosain, MD, MBARohit Gosain, MD

Raajit Rampal, MD, PhD

08/19/2026

Ep. 1: The JAK Inhibitor Paradigm and Unmet Needs in Myelofibrosis

Nikolai Podoltsev, MD, PhDRaajit Rampal, MD, PhDSrinivas Tantravahi, MBBS, MRCPPankit Vachhani, MDRahul Gosain, MD, MBARohit Gosain, MD

Raajit Rampal, MD, PhD

08/11/2026

Selinexor Combination Therapy in Myelofibrosis: SENTRY Trial Insights

Nikolai Podoltsev, MD, PhDRaajit Rampal, MD, PhDSrinivas Tantravahi, MBBS, MRCPPankit Vachhani, MDRahul Gosain, MD, MBARohit Gosain, MD

Myelofibrosis treatment algorithm 2025, oncological updates by Dr. Raajit Rampal and experts in hematology and cancer research.

Raajit Rampal, MD, PhD

Midhun Malla, MDRachna Shroff, MD, MS, FASCO

Rafael Fonseca, MD

View All

Rafael Fonseca, MD

07/10/2026

Ep 4. Community Perspective: Partnerships and Outpatient Strategies for Bispecifics in Multiple Myeloma

Rohit Gosain, MDRahul Gosain, MD, MBAS. Vincent Rajkumar, MDRafael Fonseca, MDBeth Faiman, CNP, PhD

Rafael Fonseca, MD

07/09/2026

Ep 3. Managing Side Effects BCMA Bispecifics and Talquetamab in Myeloma

Rohit Gosain, MDRahul Gosain, MD, MBAS. Vincent Rajkumar, MDRafael Fonseca, MDBeth Faiman, CNP, PhD

Rafael Fonseca, MD

07/08/2026

Ep 2. The Advent of Bispecifics: MajesTEC-3, MajesTEC-9, and MonumenTAL-3

Rohit Gosain, MDRahul Gosain, MD, MBAS. Vincent Rajkumar, MDRafael Fonseca, MDBeth Faiman, CNP, PhD

Rafael Fonseca, MD

Rahul Banerjee, MD, FACPHamza Hashmi, MD

Rahul Banerjee, MD, FACP

09/30/2026

Ep. 1: Moving Closer to a Cure in Multiple Myeloma Treatment

Rahul Banerjee, MD, FACPHamza Hashmi, MD

Rahul Banerjee, MD, FACP

07/22/2026

The Emerging Data for CELMoDs in Multiple Myeloma

Rahul Banerjee, MD, FACPRohit Gosain, MD

Rahul Banerjee, MD, FACP

07/07/2026

5 Key Multiple Myeloma Trial Updates From EHA 2026

Rohit Gosain, MDRahul Gosain, MD, MBARahul Banerjee, MD, FACP

Rahul Gosain, MD, MBA

View All

Group photo of three doctors discussing gastric and GEJ cancer treatment options.

Nataliya Uboha, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

$OncUpdates article featuring Dr. Sagar Lonial, Dr. Rahul Gosain, and Dr. Rohit Gosain discussing treatment options for relapsed or refractory multiple myeloma.$

Matthew Kurian, MDWassim McHayleh, MDEleonora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD

Group photo of three doctors, including Dr. Thomas LeBlanc, Dr. Rohit Gosain, and Dr. Rahul Gosain, discussing treatment options for lower-risk myelodysplastic syndrome.

Rahul Gosain, MD, MBA

08/17/2026

Critical Role of Luspatercept in the Treatment of Lower-Risk Myelodysplastic Syndrome

Thomas LeBlanc, MD, MARahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

08/11/2026

Selinexor Combination Therapy in Myelofibrosis: SENTRY Trial Insights

Nikolai Podoltsev, MD, PhDRaajit Rampal, MD, PhDSrinivas Tantravahi, MBBS, MRCPPankit Vachhani, MDRahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

08/11/2026

Ongoing Dialogue: A Team-Based Approach to Pancreatic Cancer Management

Timothy Brown, MD, MSCEHeather Kline, MS, APRN, FNP-CRahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

08/07/2026

Ep. 4: Personalizing Therapy Decisions in Lower-Risk Myelodysplastic Syndromes

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Rahul Gosain, MD, MBA

08/06/2026

Treatment Options and Sequencing for Late Relapsed/Refractory Multiple Myeloma

Maximilian Merz, MDRahul Gosain, MD, MBARohit Gosain, MD

Promotional image for OncUpdates featuring Dr. Shaji Kumar, Dr. Rohit Gosain, and Dr. Rahul Gosain discussing navigating first relapse in multiple myeloma.

Rahul Gosain, MD, MBA

08/06/2026

Navigating First Relapse in Multiple Myeloma

Shaji Kumar, MDRahul Gosain, MD, MBARohit Gosain, MD

Group photo of four medical professionals, including Dr. Shaji Kumar, Dr. Vincent Rajkumar, Dr. Rahul Gosain, and Dr. Rohit Gosain, discussing findings from ENDURANCE trial for multiple myeloma.

Hope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Dr. Sara Tolaney, Dr. Rahul Gosain, and Dr. Rohit Gosain discuss new indications for Sacituzumab Govitecan in TNBC.

Aaron Gerds, MDAnthony M. Hunter, MDAnand Patel, MDRahul Gosain, MD, MBARohit Gosain, MD

Binod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

06/04/2026

Clinical Insights: Integrating Durvalumab Into Non–Muscle-Invasive Bladder Cancer Care

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Prominent oncology experts Dr. Shirish Gadgeel, Dr. Wade Iams, Dr. Rohit Gosain, and Dr. Rahul Gosain discuss advanced treatment and management options for mEGFR NSCLC patients.

Rahul Gosain, MD, MBA

06/04/2026

Experts Review Best Practices in Metastatic EGFR–Mutated NSCLC Cases

Shirish Gadgeel, MBBS, FASCOWade Iams, MD, MSCIRahul Gosain, MD, MBARohit Gosain, MD

Erika Hamilton, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Group photo of three medical professionals discussing BRAF and MEK inhibitor side effects in NSCLC, featuring Dr. Melissa Johnson, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Rahul Gosain, MD, MBA

05/28/2026

BRAF and MEK Inhibitor Side Effects in BRAF V600E–Mutated NSCLC

Melissa Johnson, MDRahul Gosain, MD, MBARohit Gosain, MD

$Experts evaluate targeted therapies for relapsed or refractory AML in challenging cases, featuring Dr. Joshua Zeidner, Dr. Rohit Gosain, and Dr. Rahul Gosain.$

Rahul Gosain, MD, MBA

05/27/2026

Experts Evaluate Targeted Therapies in Relapsed or Refractory AML

Joshua Zeidner, MDRahul Gosain, MD, MBARohit Gosain, MD

Medical professionals discussing treatment options for BRAF V600E-mutated NSCLC, highlighting personalized approaches and targeted therapies for lung cancer patients.

Rahul Gosain, MD, MBA

05/26/2026

How To Select Between Treatment Options for BRAF V600E–Mutated NSCLC

Gregory Riely, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

05/25/2026

Challenging Cases: Frontline TKI for CML and Options Upon Progression

Fadi Haddad, MDGabriela Hobbs, MDRahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

05/20/2026

Bispecific Therapy in Multiple Myeloma: Strategies for Managing Toxicities

Hamza Hashmi, MDCesar Rodriguez, MDRahul Gosain, MD, MBARohit Gosain, MD

Advanced frontline therapy for metastatic NSCLC without actionable mutations.

Rahul Gosain, MD, MBA

05/18/2026

The Frontline Treatment Algorithm for Metastatic NSCLC Without Actionable Mutations

Chirstine Garcia, MD, MPHRahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

05/18/2026

How To Manage Side Effects of EGFR Inhibitors in NSCLC

Azam J. Farooqui, MDJoshua Sabari, MDRahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

05/15/2026

Frontline Treatments for Metastatic NSCLC With Actionable Mutations

Eric Singhi, MDRahul Gosain, MD, MBARohit Gosain, MD

Expert medical team discussing curative treatment options for early-stage non-small cell lung cancer (NSCLC).

Rahul Gosain, MD, MBA

05/11/2026

Standard of Care Curative Treatments for Early-Stage NSCLC

Sanjay Popat, FRCP, PhDRahul Gosain, MD, MBARohit Gosain, MD

Expert guidance on managing side effects of colorectal cancer therapies, featuring Dr. Rona Yaeger and colleagues, for improved patient care and treatment outcomes.

Rahul Gosain, MD, MBA

05/06/2026

How to Manage Side Effects of Colorectal Cancer Therapies

Rona Yaeger, MDRahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

05/05/2026

Standard of Care in SCLC: Treatment Across Limited- and Extensive-Stage Disease

Jacob Sands, MDRahul Gosain, MD, MBARohit Gosain, MD

Dr. Scott Kopetz discusses a new treatment option for metastatic colorectal cancer with BRAF V600E mutation, featuring experts Dr. Rahul Gosain and Dr. Rohit Gosain.

Rahul Gosain, MD, MBA

04/30/2026

BREAKWATER: New Treatment Option for Metastatic Colorectal Cancer With BRAF V600E Mutation

Scott Kopetz, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

An image showing Dr. Smitha Krishnamurthi and colleagues discussing colorectal cancer treatment standards.

Rahul Gosain, MD, MBA

04/27/2026

Assessing the Current Standard of Care Treatment for Colorectal Cancer

Smitha Krishnamurthi, MDRahul Gosain, MD, MBARohit Gosain, MD

Medical professionals discussing the latest advancements in pancreatic cancer treatment algorithms, highlighting personalized approaches and innovative therapies.

Rahul Gosain, MD, MBA

04/21/2026

The Evolving Treatment Algorithm for Pancreatic Cancers

Shubham Pant, MD, MBBSRahul Gosain, MD, MBARohit Gosain, MD

Doctors review the current biliary tract cancer treatment algorithm, featuring Dr. Suneel Kamath, Dr. Rohit Gosain, and Dr. Rahul Gosain, in a professional medical setting.

Rahul Gosain, MD, MBA

04/15/2026

Review of the Current Biliary Tract Cancer Treatment Algorithm

Suneel Kamath, MDRahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

04/06/2026

The Updated Treatment Algorithm for Bladder Cancer

Stephanie Berg, DOJoshua Meeks, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

03/31/2026

Reviewing the RCC Treatment Algorithm and Novel Trial Regimens

Katy Beckermann, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Prostate cancer treatment experts review algorithms, featuring Dr. Scott Tagawa, Dr. Rohit Gosain, and Dr. Rahul Gosain, highlighting innovative approaches and recent advancements in oncology care.

Rahul Gosain, MD, MBA

03/26/2026

Experts Review Treatment Algorithms for Prostate Cancer

Scott Tagawa, MD, MS, FACP, FASCORahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

03/25/2026

Bladder, Kidney, and Prostate Cancer Highlights From ASCO GU 2026

Petros Grivas, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

An informative image featuring Dr. Tiffany Traina and Dr. Rohit Gosain with Dr. Rahul Gosain, highlighting treatment algorithms across TNBC populations for oncology research and clinical practice.

Rahul Gosain, MD, MBA

03/18/2026

Treatment Algorithms Across TNBC Populations

Tiffany Traina, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

03/15/2026

Ep. 4: Multidisciplinary Approaches to Emerging Bladder Cancer Treatments

Rahul Gosain, MD, MBARohit Gosain, MDMatt Galsky, MDSia Daneshmand, MDChad Reichard, MDShilpa Gupta, MD

Rahul Gosain, MD, MBA

03/14/2026

Ep. 3: Optimizing Perioperative ADC and Immunotherapy in Muscle-Invasive Bladder Cancer

Rahul Gosain, MD, MBARohit Gosain, MDMatt Galsky, MDSia Daneshmand, MDChad Reichard, MDShilpa Gupta, MD

Rahul Gosain, MD, MBA

03/12/2026

Ep. 2: Coordinating Systemic Therapy and Radical Cystectomy in Muscle-Invasive Bladder Cancer

Rahul Gosain, MD, MBARohit Gosain, MDMatt Galsky, MDSia Daneshmand, MDChad Reichard, MDShilpa Gupta, MD

Rahul Gosain, MD, MBA

03/11/2026

Ep. 1: NIAGARA: Shifting the Treatment Landscape in Muscle-Invasive Bladder Cancer

Rahul Gosain, MD, MBARohit Gosain, MDMatt Galsky, MDShilpa Gupta, MDSia Daneshmand, MDChad Reichard, MD

Advanced medical professionals discussing treatment considerations and safety updates in metastatic pancreatic adenocarcinoma, with a cityscape background emphasizing healthcare expertise and research.

Rahul Gosain, MD, MBA

03/10/2026

Treatment Considerations and Safety Updates in Metastatic Pancreatic Adenocarcinoma

Rahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

03/10/2026

Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Muscle-Invasive Bladder Cancer in KEYNOTE-B15/EV-304

Rahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

03/10/2026

Teclistamab Plus Daratumumab Approved for Relapsed or Refractory Multiple Myeloma After MajesTEC-3

Luciano Costa, MDRahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

03/09/2026

Clinical Insights: Evolving Landscapes in MIBC and NMIBC

Rahul Gosain, MD, MBARohit Gosain, MDShilpa Gupta, MDChad Reichard, MDSia Daneshmand, MDMatt Galsky, MD

Advanced breast cancer treatment algorithm discussion featuring Dr. Virginia Kaklamani, Dr. Rohit Gosain, and Dr. Rahul Gosain, highlighting the evolving landscape of HER2-positive breast cancer manag.

Rahul Gosain, MD, MBA

03/06/2026

Treatment Algorithm: The Shifting Landscape of HER2-Positive Breast Cancer

Virginia Kaklamani, MD, DScRahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

03/05/2026

Adjuvant Carboplatin and PARP Inhibitor Combination Trials in TNBC

Rebecca Shatsky, MDRahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

03/04/2026

AML and CML Highlights From ASH 2025

Jorge Cortes, MDRahul Gosain, MD, MBARohit Gosain, MD

Expert panel discussing clinical implications of Enfortumab Vedotin plus Pembrolizumab in cisplatin-ineligible metastatic bladder cancer at OncUpdates.

Rahul Gosain, MD, MBA

03/03/2026

Transformative Data in Cisplatin-Ineligible MIBC: Clinical Implications of Enfortumab Vedotin Plus Pembrolizumab

Thomas Powles, MD, MBBS, MRCPRahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

03/02/2026

Standard of Care Treatments for HR+ Metastatic Breast Cancer

Kevin Kalinsky, MD, MS, FASCORahul Gosain, MD, MBARohit Gosain, MD

Rahul Gosain, MD, MBA

02/26/2026

Bispecifics, BTK Inhibitors, and Immunotherapy Drive Lymphoma Advances

David Braun, MD, PhDBradley McGregor, MDUlka Vaishampayan, MBBSRahul Gosain, MD, MBARohit Gosain, MD

$Because I can't access external links or view images, I can't analyze the specific image from the URL provided. However, based on the description and context related to "OncUpdates" and the title "Selecting Treatments for Cases in Relapsed or Refractory RCC," I can generate SEO-optimized text for a typical promotional or informational medical image related to this topic.$

Rahul Gosain, MD, MBA

12/05/2025